[go: up one dir, main page]

AU2001264077C1 - Serine protease inhibitors - Google Patents

Serine protease inhibitors Download PDF

Info

Publication number
AU2001264077C1
AU2001264077C1 AU2001264077A AU2001264077A AU2001264077C1 AU 2001264077 C1 AU2001264077 C1 AU 2001264077C1 AU 2001264077 A AU2001264077 A AU 2001264077A AU 2001264077 A AU2001264077 A AU 2001264077A AU 2001264077 C1 AU2001264077 C1 AU 2001264077C1
Authority
AU
Australia
Prior art keywords
compound
alkyl
group
amino
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001264077A
Other versions
AU2001264077B2 (en
AU2001264077A1 (en
Inventor
Christopher Neil Farthing
Martin James Harrison
Keith Michael Johnson
Sarah Elizabeth Lively
Bohdan Waszkowycz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tularik Ltd
Original Assignee
Tularik Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2000/002291 external-priority patent/WO2000077027A2/en
Priority claimed from PCT/GB2000/004764 external-priority patent/WO2001044226A1/en
Application filed by Tularik Ltd filed Critical Tularik Ltd
Publication of AU2001264077C1 publication Critical patent/AU2001264077C1/en
Publication of AU2001264077A1 publication Critical patent/AU2001264077A1/en
Application granted granted Critical
Publication of AU2001264077B2 publication Critical patent/AU2001264077B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

WO 01/96305 PCT/GB01/02566 SERINE PROTEASE INHIBITORS This invention relates to compounds which are inhibitors of the serine protease, tryptase, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More particularly it relates to compounds for use in the treatment of mast cell mediated diseases such as asthma and other allergic and inflammatory conditions, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body.
Asthma, the most prevalent of all mast cell mediated conditions affects about 5% of the population in industrialised countries and there is evidence that its incidence and severity are on the increase. Furthermore, the incidence of childhood asthma is rising and there are suggestions of a link between environmental pollutants and the onset of the disease.
Initially, it was believed that bronchoconstriction, i.e.
the narrowing of the airways in the lungs, was the major feature of asthma. However, it is now recognised that inflammation in the lungs is an integral part of the development of the disease.
The inhalation of an allergen by an asthmatic generates a strong immune system response which triggers release of inflammatory mediators, including histamine and leukotrienes from inflammatory cells. These increase the permeability of the blood vessel walls, attract inflammatory cells into the tissues and contract the smooth muscle around the airways. As a result, fluid leaks from the blood and the tissues swell, further narrowing the airways. The inflammatory cells cause damage to the epithelial cells lining the airways exposing nerve endings which stimulates secretion of mucous as well as augmenting the inflammation by causing the release of neurokinins.
Thus asthma is a complex disease frequently characterised by progressive developments of hyper-responsiveness of the trachea and bronchi as a result of chronic inflammation reactions which irritate the epithelium lining the airway and WO 01/96305 PCT/GB01/02566 -2cause pathological thickening of the underlying tissues.
Leukocytes and mast cells are present in the epithelium and smooth muscle tissue of the bronchi where they are activated initially by binding of specific inhaled antigens to IgE receptors. Activated mast cells release a number of preformed or primary chemical mediators of the inflammatory response in asthma as well as enzymes. Moreover, secondary mediators of inflammation are generated by enzymatic reactions of activated mast cells and a number of large molecules are released by degranulation of mast cells.
It has therefore been proposed that chemical release from mast cells probably accounts for the early bronchiolar constriction response that occurs in susceptible individuals after exposure to airborne allergens. The early asthmatic reaction is maximal at around 15 minutes after allergen exposure, recovery occurring over the ensuing 1 to 2 hours. In approximately 30% of individuals, the early asthmatic reaction is followed by a further decline in respiratory function which normally begins within a few hours and is maximal between 6 and 12 hours after exposure. This late asthmatic reaction is accompanied by a marked increase in the number of inflammatory cells infiltrating bronchiolar smooth muscle and epithelial tissues, and spilling into the airways. These cells are attracted to the site by release of mast cell derived chemotactic agents.
The most straightforward way of dealing with an asthma attack is with a bronchodilator drug which causes airways to expand. The most effective bronchodilators are the 3adrenergic agonists which mimic the actions of adrenalin.
These are widely used and are simply administered to the lungs by inhalers. However, bronchoconstrictor drugs are primarily of use in short term symptomatic relief, and do not prevent asthma attacks nor deterioration of lung function over the long term.
Anti-inflammatory drugs such as cromoglycate and the corticosteroids are also widely used in asthma therapy.
Cromoglycate has anti-inflammatory activity and has been found to be extremely safe. Although such cromolyns have minimal WO 01/96305 PCT/GB01/02566 -3side effects and are currently preferred for initial preventive therapy in children, it is well known that they are of limited efficacy.
The use of corticosteroids in asthma therapy was a major advance since they are very effective anti-inflammatory agents, however, steroids are very powerful, broad spectrum anti-inflammatory agents and their potency and non-specificity means that they are seriously limited by adverse side effects.
Localising steroid treatment to the lungs using inhaler technology has reduced side effects but the reduced systemic exposure following inhalation still results in some undesirable effects. Hence, there is a reluctance to use steroids early in the course of the disease.
There therefore still remains a need for an alternative asthma therapy which is a safe, effective, anti-inflammatory or immunomodulatory agent which can be taken to treat chronic asthma.
Tryptase is the major secretory protease of human mast cells and is proposed to be involved in neuropeptide processing and tissue inflammation. Tryptase is one of a large number of serine protease enzymes which play a central role in the regulation of a wide variety of physiological processes including coagulation, fibrinolysis, fertilization, development, malignancy, neuromuscular patterning and inflammation. Although a large number of serine proteases have been widely investigated, tryptase still remains relatively unexplored.
Mature human tryptase is a glycosylated, heparinassociated tetramer of catalytically active subunits. Its amino-acid structure appears to have no close counterpart among the other serine proteases which have been characterised. Tryptase is stored in mast cell secretory granules and after mast cell activation, human tryptase can be measured readily in a variety of biological fluids. For example, after anaphylaxis, tryptase appears in the blood stream where it is readily detectable for several hours.
Tryptase also appears in samples of nasal and lung lavage fluid from atopic subjects challenged with specific antigen.
WO 01/96305 PCT/GB01/02566 -4- Tryptase has been implicated in a variety of biological processes where activation and degranulation of mast cells occur. Accordingly, mast cell tryptase inhibition may be of great value in the prophylaxis and treatment of a variety of mast cell mediated conditions. Mast cells can degranulate by both IgE-dependent and independent mechanisms thereby implicating tryptase in both atopic and non-atopic inflammatory conditions. Tryptase can activate proteases such as pro-urokinase and pro-MMP3 (pro-matrix metalloprotease 3, pro-stromelysin), thereby indicating a pathological role in tissue inflammation and remodelling. Furthermore, the recent evidence that tryptase can activate certain G-protein coupled receptors (eg PAR2) and induce neurogenic inflammation points to a broader physiological role, for example in modulating pain mechanisms. Given tryptase's multiple mechanisms of action, it has been proposed that tryptase inhibitors may be beneficial in a broad range of diseases. These include conditions such as: asthma (specifically influencing the inflammatory component, the underlying hyperreactivity, and the chronic fibrotic damage due to smooth muscle thickening); chronic obstructive pulmonary disease (COPD) and pulmonary fibrotic diseases; rhinitis; psoriasis; urticaria; dermatitis; arthritis; Crohn's disease; colitis; angiogenesis; atherosclerosis; multiple sclerosis; interstitial cystitis; migraine headache; neurogenic inflammation and pain mechanisms; wound healing; cirrhosis of the liver; Kimura's disease; pre-eclampsia; bleeding problems associated with menstruation and the menopause; cancer (particularly melanoma and tumour metastasis); pancreatitis; and certain viral infections (Yong, Exp. Toxic Pathol, 1997, 49, 409; Steinhoff et al., Nat. Med., 2000, 6, 151; Downing and Miyan, Immunol.
Today, 2000, 21, 281; Tetlow and Wooley, Ann. Rheum. Dis., 1995, 54, 549; Jeziorska, Salamonsen and Wooley, Biol.
Reprod., 1995, 53, 312; Brain, Nat. Med., 2000, 6, 134; Olness et al., Headache, 1999, 39, 101.) The underlying principle is that a tryptase inhibitor should have utility where mast cells have being induced to degranulate by whatever mechanism, including anaphylactic reactions due to exogenous substances, e.g. morphine-induced bronchoconstriction (Bowman and Rand, Textbook of Pharmacology, 2 n d edt., 1980.) In W096/09297, W095/32945, W094/20527 and US 5,525,623 a variety of peptide based compounds are suggested as potential inhibitors of the mast cell protease tryptase. In W095/03333 a tryptase inhibitor is provided by a polypeptide obtainable from the leech hirudo medicinalis. In W096/08275 secretory leukocyte protease inhibitor (SLPI) and active fragments thereof have been found to inhibit the proteolytic activity of tryptase. In W099/55661 certain 4-aminomethylbenzoic ester derivatives are proposed as potential tryptase inhibitors.
We have now found that certain aromatic compounds carrying lipophilic side chains are particularly effective as inhibitors of the serine protease, tryptase. Certain of these compounds have further been found to have good oral bioavailability.
It is envisaged that the compounds of the invention will be useful not only in the treatment and prophylaxis of asthma but also of other allergic and inflammatory conditions mediated by tryptase such as allergic rhinitis, skin conditions such as eczema, psoriasis, atopic dermatitis and urticaria, rheumatoid arthritis, conjunctivitis, inflammatory bowel disease, neurogenic inflammation, atherosclerosis and cancer.
In a first aspect the present invention provides a tryptase, inhibitor compound of formula (I) Rs Cy X L Lp
H
2 N
R
6 a WO 01/96305 WO 0196305PCT/GB01/02566 where: R, represents amino, hydroxy, aminomethyl, hydroxymethyl or hydrogen; represents hydrogen or methyl; X-X is selected from -CH=CE-, -CONRia,, -NH-C0, -NRia-CH,-,
-CH
2 -NRia,-, -CH 2
-OCH
2 -Coo-, -OC=O- and -CHCH 2 Ria represents hydrogen, (1-6C)alkyl or phenyl(I-6C)alkyl; L is CO or CONRd(CH 2 in which m is 0 or 1 and Ria is hydrogen, (1-CC)alkyl or phenyl(1-6C)alkyl; Cy represents cycloalkyl, piperidinyl, 3,4methylenedioxyphenyl, furyl, thienyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl, pyrazinyl, naphthyl, indolyl, indanyl, 3,4-dihydrobenzofuryl, benzofuryl or benzo[blthienyl group, optionally substituted by R~a or R 3 iXi in which X. is a bond, 0, NH, CH,, CO, CONH, NHCC, C0,, NHSO, or SONH and R 3 i is phenyl or pyridyl optionally substituted by R 3 each R 3 independently is hydrogen, hydroxyl, (1-6C) alkoxy, (1-CC) alkyl, (2-6C)alkenyl, (2-CC)alkynyl, (1- GC)alkanoyl, (1-CC) alkylaminoalkyl, hydroxy(J-6C) aikyl, carboxy, (1-6C) alkoxyalkyl, (1-6C) alkoxycarbonyl, (1-6C) alkylaminocarbonyl, amino (1-6C) alkyl, CONH 2
CH
2
CONH
2 aminoacetyl, (1-CC) alkanoylamino, hydroxy(1-6C)alkanoylamino, amino (1-60) alkanoylamino, (1-60) alkylamino (1-CC) alkanoylamino, di(l-6C)alk-ylamino(l-6C)alkanoylamino, (1-6C) alkoxycarbonylamino, amino, halo, cyano, nitro, thiol, (1-CC) alkylthio, (1-6C) alkylsuiphonyl, (1-6C) alkylsuiphenyl, imidazolyl, hydrazido, (1-CC) alkylimidazolyl, (1-6C) alkylsulphonamido, (1 -6C) alkylaminosulphonyl, aminosulphonyl, (1-CC) haloalkoxy, or (1-CC) haloalkyl; and Lp is a lipophilic group; or a physiologically tolerable salt thereof, e.g. a halide, phosphate or sulphate salt or a salt with ammonium or an organic amine such as ethylamine or meglumine.
Compounds of formula I have surprisingly been found to be particularly effective as inhibitors of tryptase and to show a surprising selectivity for tryptase over other serine proteases.
In the compounds of the invention, R, preferably WO 01/96305 PCT/GB01/02566 -7represents amino or hydrogen, more preferably hydrogen.
R
6 a preferably represents hydrogen.
In the compounds of the invention, the alpha atom preferably has the conformation that would result from construction from a D-a-aminoacid NH 2 -CH(Cy)-COOH where the NH 2 represents part of X-X.
In the compounds of the invention, unless otherwise indicated, aryl groups preferably contain 5 to 10 ring atoms optionally including 1, 2 or 3 heteroatoms selected from O, N and S; alkyl, alkenyl or alkynyl groups or alkylene moieties preferably contain up to 6 carbons, e.g. or cyclic groups preferably have ring sizes of 3 to 8 atoms; and fused multicyclic groups preferably contain 8 to 16 ring atoms.
R, is preferably hydrogen.
X-X may, for example, be selected from -CH=CH-, -CONR,,-, -NH-CO-, -CHO-, -COO-, -OC=0- and
-CH
2
CH
2 Preferably, the X moiety nearest to the alpha atom is an NH or O atom, most preferably an NH group. The X moiety alpha to the aromatic ring is preferably a carbon based group such as CH 2 or CO, preferably CO. Thus a particularly preferred linker X-X is -CONH-.
Examples of particular values for Rid are: hydrogen; for (1-6C)alkyl: methyl or ethyl; and for phenyl(l-6C)alkyl: benzyl or phenylethyl.
Rid is preferably hydrogen.
Examples of particular values for L are CO, CONH, CON(CH) and CONHCH,, more preferably CO, CONH or CON(CH,).
It will be appreciated by those skilled in the art that a diverse range of organic groups are lipophilic, and that it is therefore impractical to define with precision each and every structure that may be incorporated into a serine protease inhibitor according to the invention. Accordingly, it is being assumed that the addressee of this specification will not require an exhaustive computer listing of structures of lipophilic groups, but will instead make use of the structures of lipophilic groups disclosed in the specification, WO 01/96305 PCT/GB01/02566 -8especially those exemplified; the test systems described herein for identifying tryptase inhibitors; and common general knowledge of the lipophilicity, synthesis and stability of organic compounds, to obtain novel inhibitor compounds of formula The lipophilic group may be, for example, an alkyl, alkenyl, carbocyclic or heterocyclic group, or a combination of two or more such groups linked by a spiro linkage or a single or double bond or by C=0, O, OCO, COO, S, SO, SO 2 CONRIe, NRIe-CO- or NRle linkage (where is as defined for optionally substituted by one or more oxo or R 3 groups in which
R
3 is an amino acid residue, N-(1-6C)alkylaminocarbonyl, N,Ndi(1-6C)alkylaminocarbonyl, N-(l-GC)alkylamino(1-6C)alkanoyl, N-(1-6C)alkanoylamino(1-6C)alkanonyl, C-hydroxyamino(1- 6C)alkanoyl, hydroxy(2-6C)alkanoylamino(1-6C)alkanoyl, di(1- 6C)alkylaminosulfonyl, hydrogen, hydroxyl, (l-6C)alkoxy, (l-6C)alkanoyloxy, (1-6C) alkyl, (2-6C)alkenyl (2-6C)alkynyl, (3-6C)alkenyloxycarbonyl, (1-6C)alkanoyl, amino(1-6C) alkyl, amido (CONH) amino(1-6C) alkanoyl, aminocarbonyl(1-5C)alkanoyl, hydroxy(1-6C)alkyl, carboxy, hydroxy(l-6C)alkanoyl, (1-6C)alkoxy(l-6C)alkyl,(1- (1-6C)alkoxycarbonyl, (1- 6C)alkanoylamino, amino, halo, cyano, nitro, thiol, (1-6C) alkylthio, (l-6C)alkylsulfonyl, (1- 6C)alkylsulphenyl and hydrazido.
Preferably the lipophilic group is a carbocyclic or heterocyclic group, or a combination of a carbocyclic or heterocyclic group with one or more alkyl, alkenyl, carbocyclic or heterocyclic groups, linked by a spiro linkage or a single or double bond or by C=O, O, OCO, COO, S, SO, SO 2 CONR,, NRie-CO- or NRe linkage (where Re is as defined for optionally substituted by one or more oxo or R, groups.
Re is preferably a hydrogen atom.
When the lipophilic group comprises an alkyl group, this may be, for example, a (1-3C) alkyl group, such as methyl, ethyl or propyl. Preferably an alkyl group is unsubstituted.
When the lipophilic group comprises a carbocyclic group, this may be, for example, a non-aromatic or aromatic, mono or WO 01/96305 PCT/GB01/02566 -9polycyclic hydrocarbon group containing up to 25, more preferably up to 10 carbon atoms. The carbocyclic group may thus be, for example, a cycloalkyl, polycycloalkyl, phenyl or naphthyl group, or a cycloalkyl group fused with a phenyl group.
Examples of particular values for a cycloalkyl group are (3-6C) cycloalkyl groups, such as cyclopentyl and cyclohexyl.
A cycloalkyl group is preferably unsubstituted or substituted by one group R 3 preferably an amino or alkyl group.
Examples of particular values for a polycycloalkyl group are (6-10C) polycycloalkyl groups, such as bicycloalkyl, for example decalinyl or norbornyl. A polycycloalkyl group is preferably unsubstituted or substituted by one, two or three R 3 groups, for example alkyl such as methyl. An example of a polycycloalkyl group substituted by alkyl is isopinocampheyl.
A phenyl group is preferably unsubstituted or substituted by one or two R, groups.
A naphthyl group is preferably unsubstituted or substituted by one R 3 group.
Examples of a cycloalkyl or cycloalkenyl group fused with a phenyl group are indanyl and tetrahydronaphthyl. This group is preferably unsubstituted or substituted by oxo or one or two R, groups. Examples of groups substituted by oxo are 1- 1-oxo-l,2,3,4-tetrahydronaphth-7-yl and 1-oxo- 1,2,3,4-tetrahydro-naphth-6-yl.
When the lipophilic group comprises a heterocyclic group, this may be, for example, a non-aromatic or aromatic, mono or polycyclic group containing one or two oxygen, nitrogen or sulfur atoms in the ring system, and in total up to 25, more preferably up to 10 ring system atoms.
Examples of a heterocyclic group when it is a nonaromatic monocyclic group are azacycloalkyl groups, such as pyrrolidinyl and piperidinyl; azacycloalkenyl groups, such as pyrrolinyl; diazacycloalkyl groups, such as piperazinyl; oxacycloalkyl groups, such as tetrahydropyranyl; oxaazacycloalkyl groups, such as morpholino; and thiacycloalkyl groups, such as tetrahydrothiopyranyl. A nonaromatic monocyclic group preferably contains 5, 6 or 7 ring WO 01/96305 PCT/GB01/02566 atoms and is preferably unsubstituted or substituted by one group R 3 Examples of a heterocyclic group when it is a nonaromatic polycyclic group are bicyclic groups, such as azacycloalkyl fused with phenyl, for example dihydroindolyl, dihydroisoindolyl, tetrahydroquinolinyl and tetrahydroisoquinolinyl; azacycloalkyl fused with cycloalkyl, such as decahydroisoquinolinyl; and thienyl fused with cycloalkyl, such as tetrahydrobenzo[b]thienyl or 4Hcyclopenta(b)thienyl. Examples of thienyl fused with cycloalkyl are 4H-cyclohepta(b)thienyl and tetrahydro-4,7methanobenzo(b)thiophenyl. Further examples of bicyclic groups are thienyl fused with a heteracycloalkyl group, such as 4,5-dihydro-5H-thieno[2,3-c]pyranyl, 4,5-dihydro-5Hthieno[2,3-c]thiopyranyl and 4,5,6,7-tetrahydrothieno[2,3b]pyridinyl.
Examples of a heterocyclic group when it is an aromatic monocyclic group are furyl, pyrrolyl, thienyl, imidazolyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl, preferably unsubstituted or substituted by one or two R 3 groups.
Examples of a heterocyclic group when it is an aromatic polycyclic group are bicyclic groups such as benzofuryl, quinolinyl, isoquinolinyl, benzothienyl, indolyl and benzothiazolyl.
Where Lp comprises a combination of at least two groups, it preferably comprises a combination of two or three such groups. The groups are preferably linked by a single bond, C=O, OCO, COO, O or NR,,.
Examples of particular values for R 3 are:for an amino acid residue: N-acetylalaninoyl, serinoyl, threoninoyl, aspartoyl or glutamoyl; for N-(l-6C)alkylaminocarbonyl: N-(1,3-dimethyl)butylaminocarbonyl; for N,N-di(l-6C)alkylaminocarbonyl: N-methyl-Nethylaminocarbonyl; for N-(l-6C)alkylamino(l-6C)alkanoyl: N-methylacetyl; for N-(l-6C)alkanoylamino(l-6C)alkanonyl: 2-N- WO 01/96305 WO 0196305PCT/GB01/02566 -11acetylaminoacetyl, 2-N-acetylaminopropanoyl or 2-N- (2methyipropanoyl) aminoacetyl; for C-hydroxyamino (l-6C) alkanoyl: 2-amino-3-hydroxypropanoyl or 2-amino-3 -hydroxybutanoyl; for hydroxy(2-6C)alkanoylamino(1-6C)alkanoyl: 2hydroxyacetylaminoacetyl; for di (1-6C) alkylaminosulfonyl: dimethylaminosulfonyl; hydrogen; hydroxyl; for (1-6C)alkoxy: methoxy; for (1-GC)alkanoyloxy: acetoxy; f or (1-6C) alkyl: methyl, ethyl, propyl, 2-propyl or 2,2dimethylethyl; for (2-GC)alkenyl: allyl; for (2-6C)alkynyl: propynyl; for (3-SC) alkenyloxycarbonyl: allyloxycarbonyl; for (1-6C)aIlkanoyl: acetyl, propionyl or isobutyryl; for amino (1-6C) alkyl: aminomethyl; amido (CONH') for amino(1-6C)alkanoyl: aminoacetyl (COCH 2 aminopropionyl
(COCH
2
CH
2 NH,) or 2 -aminopropionyl (COCK (CH 3
NH
2 for aminocarboiyl (1-SC) alkanoyl: aminocarbonylacetyl; for hydroxy 6C) alkyl: hydroxymethyl or l-hydroxyethyl; carboxy; for hydroxy(l-6C)alkanoyl: 2-hydroxyacetyl or 2hydroxypropanoyl; for (1-6C)alkoxy(l-6C)alkyl: methoxymethyl; for (1-6C) alkoxycarbonyl (1-SC) alkyl: methoxycarbonylmethyl; for (1-6C)aJlkoxycarbonyl: methoxycarbonyl or ethoxycarbonyl; for (1-6C)alkanoylamino: formylamino or acetylamino; amino; for halo: chioro; cyano; nitro; thiol; for (1-6C)alkylthio: methyithia; for (1-6C) alkylsulfonlyl: methylsuiphonyl or ethylsulfonyl; for (1-6C) alkylsulphenyl: methylsulphenyl; and WO 01/96305 WO 0196305PCT/GB01/02566 -12hydrazido.
Further examples of particular values for R, are:for N-(l-6C)alkylaminocarbonyl: N-methylaminocarbonyl or Nisobutylaminocarbonyl; and for N,N-di (1-6C) alkylaminocarbonyl: N,N-dimethylaminocarbonyl or N, N-diethylaminocarbonyl.
Most preferably, the lipophilic group is selected from
-N
(DR
S
\R
3 NC
R
3 NR3
S/
X=X
R3
N
N X
R,
WO 01/96305 WO 0196305PCT/GB01/02566 -13-
R
cc 3
N
N
R
0// m N Y
R
3 WO 01/96305 PCT/GB01/02566 -14- WO 01/96305 WO 0196305PCT/GB01/02566 -is- 0 N-CO
N
S-;aR
R
3
N
WO 01/96305 PCT/GB01/02566 -16-
R
3
,R
3 N3[ I or additionally from NR3 R3 R3 R 3 S S R3 R3INR3 S 3 wherein R 3 is as hereinbefore defined; and X represents CH or N.
In the Lp groups depicted above, preferably L represents CO when the Lp group is linked to L through N, or CONR, (such as CONH or CONCH 3 when the Lp group is linked to L through C.
One group of compounds of particular interest is that in which L represents CO and Lp represents
-NR
R 3 -N R3 WO 01/96305 WO 0196305PCT/GB01/02566 -17- -N NR 3
NR
3 C R 3 CN NJ In this group of compounds, R, preferably represents hydrogen, hydroxyl or (1-6C) alkylaminocarbonyl.
Examples of particular values for Lp in this sub-group are pyrrolidin-l-yl, piperidin-l-yl, N-methyl, Nethylaminocarbonylpiperidin-l-yl, decahydroisoquinolin-2-yl and 2,3 -dihydroindol- l-yl.
Another group of compounds of particular interest is that in which L represents CONRid (such as CONI or CONCH,) and Lp represents N such asN
R
3
R
3 Ra 14 '15 '55- N such as N or N N X 0No such as R R3- WO 01/96305 WO 0196305PCT/GB01/02566 -18-
R
3
NN
S 3N R3SR
SS
S
R
3
S
R3 R 3 in which X is CH or N.
In this group of compounds, each R, is preferably selected independently from Hydrogen, amino, hydroxy, (1-EC)alkyl, (1- 6C)alkanoyl, (l-6C) alkanoyloxy, (1-5C) alkoxycarbonyl (1- 6C)alkyl, amino(l-GC)alkyl or cyano.
Thus, values for R. in this group include hydrogen, amino, hydroxy, alkyl or aminoalkyl.
Examples of particular values are; 2 -aminocyclohexyl; (ii) 2-aminobenzothiazol--yl; (iii) quinolin-3-yl or 8-acetoxyquinolin-2-yl; (iv) 4-piperidin-l-ylphenyl or 4-piperazin-1-ylphelyl; 1 -oxoindan- (vi) (vii) tetrahydronaphth-6-yl or 1-methyltetrahydronaphth---yl; (viii) 1-oxotetrahydronaphth-6-yl or 1-oxotetrahydronaphth-7yl; (ix) 2, N-benzyl-3-acetylifldol-5-yl or N-benzyl-3-acetylildol-7- WO 01/96305 WO 0196305PCT/GB01/02566 -19yl; (xi) 3-ethoxycarbonyl-4, 5-diinethylthien-2-yl; (xii) 4-methyl-5-acetylthiazol-2-yl, 4,5-dimethylthiazol-2-yl, 4-methyl-5-ethoxycarbonylthiazol-2-yl, 3-cyano-4-mrethyl-5ethoxycarbonylthiazol -2 -yl or 4 -rethoxycarbonylmethyl methyithiazol -2 -yl; (xiii) 5-phenylthiazol-2-yl; (xiv) 2-methoxycarbonyl-5- (t-butyl) thien-3-yl; (xv) 2-acetyl-5-phenylthien-3-yl; and (xvi) -1,6-dihydro-3-raethoxycarbonyl-4H-cyclopelta thiophen- 2-yl.
Another group of compounds of particular interest is that in which L represents CONR 1 d (such as CONH or CONCH 3 and Lp represents in which R 3 is (1-6C) alkylaminocarbonyl, N- (1-6C) alkylamino,(I- 6C)alkanoyl, N- (l-6C)alkanoylamino(1-GC)alkanonyl, Chydroxyamino (1-GC) alkanoyl, hydrogen, (1-6C) alkoxy, (1- 6C)alkyl, amino (i-Ge)alkyl, aminocarbonyl, hydroxy(1-GC) alkyl, (1-6C)alkoxy(l-GC)alkyl, (1-GC)alkoxycarbonyl, (1- GC) acyloxymethoxycarbonyl, (l-6C) alkylamino, amino, halo, cyano, nitro, thiol, (1-6C) alkylthio, (1-Ge) alkylsuiphonyl, (1-Ge) alkylsuiphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, (l-GC)alkylimidazolyl, thiazolyl, (I- 6C) alkylthiLazolyl, (1-SC) alkyloxazolyl, oxazolyl, (1- SC) alkylsulphonamido, (1-Ge) alkylaminosuiphonyl, aminosuiphonyl, (1-SC)haloalkoxy or (1-6C)haloalkyl.
Preferably the phenyl group is unsubstituted or substituted by one or two R, groups.
Examples of particular values are phenyl, 3-cyano-4methyiphenyl, 3 -aminocarbonylphenyl, 4 -aminocarbonyiphenyl, 4chloro-3 -aminocarbonylphenyl, 4 -chlorophenyl, 3, dichiorophenyl, 3 -aminomethyiphenyl, 4-methyl -3acetylaminophenyl, 4- (1-hydroxethyl) phenyl and 4isopropylphenyl.
Another particular group of compounds of formula I is WO 01/96305 WO 0196305PCT/GB01/02566 that in which L represents CONR 1 d (such as CONH or CONCH,) and Lp represents Ro R 3 NN N R 3 S or or S In this group of compounds, the heterocyclic group is preferably substituted by one or two R, groups. Each R, group is preferably selected from hydrogen, halogen such as chlorine, (1-6C)alkyl, such as methyl, and (l-6C)alkoxy, such as methoxy.
Accordingly, examples of particular values for Lp are: benzothiazol-2-yl, 4-chlorobenzothiazol-2-yl, 4-methylbenzothiazol-2-yl, 6-methylbenzothiazoi-2-yl, 4-methoxybenzothiazol-2-yl and 5, G-dimethylbenzothiazol-2-yl. Further examples are 4-rethaoxy-7-methylbenzothiazol-2-yl, 6nitrobenzothiazol-2-yl, 4, 7-dimethoxybenzothiazol-2-yl, 4,5,6,7-tetrahydrobenzothiazol-2-yl, 5-methyl-4,5,6,7tetrahydrobenzothiazol-2-yl, 6-methyl-4,5, 6,7tetrahydrobenzothiazol-2-yl, 5-ethyl-4, 5,6,7tetrahydrobenzothiazol-2-yl and 7-ethyl-4, 5,5,7tetrahydrobenzothiazol-2 -yl.
Another particular group of compounds of formula I is that in which L represents CONRId (such as CONH or CONCH,) and Lp represents
N
R 3 1 in which R 3 represents R 3 or a group of formula 1 Y)P- (G 1 -Rj in which p is 0 or 1; X, represents CO, COO, CONH or SO 2
G,
represents (l-3C)alkanediyl, CHOCH, or, when p is 1, a bond; and Rj represents a carbocyclic or heterocyclic group, WO 01/96305 PCT/GB01/02566 -21optionally substituted by R 3 Within this group of compounds, a sub-group of compounds may be identified in which R3x represents R 3 or a group of formula -Rj in which p is 0 or 1 and G 1 represents (1-3C)alkanediyl or, when p is 1, a bond.
It will be appreciated that when Lp represents a group as described above, it corresponds to a group in which Lp is a combination of a heterocyclic group (2,3-dihydroindolyl), a carbocyclic or heterocyclic group (Rj) and optionally an alkyl group which groups are linked by a single bond or a carbonyl group. Accordingly, examples of particular values for Rj are the examples given above for a carbocyclic or heterocyclic group forming part of Lp. Particular mention may be made of pyrrolidinyl, such as pyrrolidin-l-yl or pyrrolidin-2-yl; piperidinyl, such as piperidin-3-yl or piperidin-4-yl; aminocycloalkyl, such as 2-aminocyclohexyl or 4-aminocyclohexyl; phenyl; 2-hydroxypheny; 3-hydroxphenyl; 4hydroxyphenyl; 4-aminomethylphenyl; 4-acetylaminomethylphenyl; 4-isopropylphenyl; 3,4-dihydroxyphenyl; naphthyl, such as 1naphthyl; quinolinyl', such as 8-quinolinyl; aminothiazolyl, such as 2-aminothiazol-4-yl; formamidothiazolyl, such as 2formamidothiazol-4-yl; imidazolyl, such as imidazol-4-yl; and pyridyl, such as pyrid-2-yl, pyrid-3-yl and pyrid-4-yl.
Examples of values for G, are a bond, -CH 2
CH
2
CH
2 and
CH
2
OCH,.
The 2,3-dihydroindolyl group in the above formula is preferably a 2,3-dihydroindol-5-yl or -6-yl group, especially a 2,3-dihydroindol-6-yl group.
Examples of structures of compounds comprising a 2,3dihydroindolyl group as described above are: WO 01/96305 WO 0196305PCT/GB01/02566 -22-
N
N R 0s NNrR
NH
WO 01/96305 WO 0196305PCT/GB01/02566 -23-
N
-01 R3 so 2 -R3
NN
N\
When R 3 is a substituent on the 1-position of a 2,3dihydroindolyl group, it preferably represents an amino acid residue; alkylaminocarbonyl; N- (1-60) alkylamino (1- 6C) alkanoyl; N-alkanoylaminoalkanonyl; C-hydroxyamino (1- 6C)alkanoyl; hydroxy(1-6C)alkanoylamino(1-6C)alkancyl; di(1L- 6C) alkylaminosulfonyl; hydrogen; (1-Ga) alkyl; (1-GC) alkanoyl; (1-60) alkoxycarbonyl; (1-60) acyloxymethoxycarbonyl; amino (1- 6C) alkyl; amido (CONH 2 amino 6C) alkanoyl; arninocarbonyl (1- GC)alkanoyl; hydroxy(1-6C)alkyl; hydroxy(1-6C)alkanoyl; (1- 6C)alkoxy(1-6C)alkyl; (l-6C)alkoxycarbonyl(1-6C)alkyl; (1alkoxycarbonyl; (1-6C) alkanoylamino; or (1- 6C)alkylsulfonyl. Examples of particular values are: Nmethylaminoacetyl, N-acetylaminoacetyl, Nacetylaminopropanoyl, N- (2-methyipropanoyl) aminoacetyl, Nacetylalaninoyl, serinoyl, threoninoyl, aspartoyl, glutamoyl, 2 -hydroxyacetylaminoacetyl, cimethylaminosulfonyl, hydrogen, methyl, acetyl, propanoyl, 2-methyipropanoyl, 3-methylbutyryl, 2 -hydroxypropanoyl, hydroxyacetyl, methoxycarbonylmethyl, methoxycarbonyl, amido, aminoacetyl, aminocarbonylacetyl, alaninoyl, methylsulfonyl or ethylsulfonyl group. Another WO 01/96305 WO 0196305PCT/GB01/02566 -24example is ethyl.
Accordingly, examples of particular values for Lp are: 1- (N-methylaminoacetyl) 3-dihydroindol-6-yl; 1- (Nacetylaminoacetyl) -2,3-dihydroindol-6-yl; 1- (Nacetylaminopropanoyl) 3-dihydroindol-6-yl; 1-N- (2methylpropanoyl~ aminoacetyl) 3-dihydroindol-6-yl; 1- (Nacetylalaninoyl) 3-dihydroindol-6-yl; 1- (serinoyl) -2,3dihydroindol-6-yl; 1- (threoninoyl) 3-dihydroindol-6-yl; I- (aspartoyl) -2,3-dihydroindol-6-yl; 1- (glutamoyl) -2,3dihydroindol-6-yl; 1- (2-hydroxyacetylamino) acetyl-2,3dihydroindol-E-y:l, 1- (2-hydroxyacetylamino) acetyl-2,3dihydroindol-6-yl, l-amido-2,3-dihydroindol-6-yl, 2,3l-methyl-2, 3-dihydroindol-6-yl; Iallyloxycarbonyl-2,3--dihydroindol-5-yl; l-acetyl-2,3dihydroindol-6-yl; l-propanoyl-2, 3-dihydroindol-6-ylF 1- (2methylpropanoyl) 3-dihydroindol-6--yl; 1- (3-methylbutyryl) 2,3-dihydroindol-6-yl; 1- (2-hydroxpropanoyl) 3-dihydroindol- G-yl; l-hydroxacetyl-2, 3-dihydroindol-6-yl; 1methoxycarbonylmethyl-2, 3-dihydroindol-G-yi; Imethoxycarbonyl-2,3-dihydroindol-6-yl; 1-aminaacetyl-2,3dihydroindol-6-yl; l-aminocarbonylacetyl-2, 3-dihydroindol-Gyl; l-alaninoyl-2,3-dihydroindol-6-yl; l-methylsulfonyl-2, 3dihydroindol-6-yl or l-ethylsulfonyl-2, 3-dihydroindol-6-yl.
Another example is l-ethyl-2, When R 3 is a substituent on a cyclohexyl, phenyl, naphthyl, thiazolyl, imidazolyl, pyridyl or quinolinyl group, it is preferably hydrogen, hydroxy, amino, alkanoylamino, alkyl, aminoalkyl or alkanoylaminoalkyl. Examples of particular values are hydrogen, hydroxy, amino, formylamino, isopropyl, aminomethyl and acetylaminomethyl.
Accordingly, further examples of particular values for Thp are: 2,3-dihydroindol-5-yl, 1- (2-aminocyclohexyl) -carbonyl- 2,3-dihydroindol-6-yl, 1- (4-aminocyclohexyl) -acetyl-2,3dihydroindol-6-yl, l-prolinoyl-2, 3-dihydroindol-6-yl, 1pyrrolidin-2-ylacetyl-2, 3-dihydroiridol-6-yl, 1-piperidin-3ylcarbonyl-2,3-dihydroindol-6-yl, l-piperidin-3-ylacetyl-2,3dihydroindol-6-yl, l-phenylacetyl-2,3-dihydroindol-6-yl, 1- (2hydroxy)phenylacetyl-2, 3-dihydroindol-6-yl, 1- (3- WO 01/96305 WO 0196305PCT/GB01/02566 hydroxy)phenylacetyl-2,3-dihydroindol-6-yl, 1- (4hydroxy)phenylacetyl-2,3-dihydroindol-6-yl, 1- (3,4dihydroxy)phenylacetyl-2, 3-dihydroindol-6-yl, 1- (4aminomethyl)phenylacetyl-2,3-dihydroindol-6-yl, 1- (4acetylaminomethyl)ph enylacetyl-2,3-dihydroindol-6-yl, 1- (4isopropyl) pheriylacetyl-2, 3-dihydroindol-6-yl, 1phenylsulfonyl-2,3-dihydroindol-6-yl, 1-benzylsulfonyl-2, 3dihydroindol-6-yl, 1-naphth-1-ylsulfonyl-2,3-dihydroindol-6yl, l-quinolin-8-ylsulfonyl-2,3-dihydroindol-6-yl, 1- (4pyridyl)acetyl-2,3-dihydroindol-6-yl, 1- (3-pyridyl)acetyl-2,3dihydroindol-6-yl, 1-imidazol-4--ylacetyl-2, 3-dihydroindol-6yl, 1- (2-aminothiazol-4-yl) acety1-2,3-dihydroindol-6-yl, and 1- (2-formamidothiazol-4-yl) acetyl-2,3-dihydroindol-6-yl, and l-benzyl-2, 3-dihydroindol-6-yl.
Another particular group of compounds of formula I is that in which Lh represents CONRad (such as CONH or CONCH,) and Lp represents R 3 y
R
3 R R R3 S or S in which R 2 y represents R 3 or a group of formula Rk*-G 2 -Xain which G 2 represents a bond or (1-3C)alkanediyl, Xa represents a bond, CO, OCO, COO or NI-CO, and R, represents a carbocyclic or heterocyclic group, optionally substituted by
R
3 It will be appreciated that when Lp represents a group as described above, it corresponds to a group in which Lp is a combination of a heterocyclic group (tetrahydrobenzothienyl), a carbocyclic or heterocyclic group (Rk) and optionally an alkyl group (G 2 which groups are linked by a single bond, or a CO, OCO, COO or NHCO group. Accordingly, examples of particular values for Rk are the examples given above for a carbocyclic or heterocyclic group forming part of Lp.
Particular mention may be made of phenyl; cycloalkyl, such as WO 01/96305 WO 0196305PCT/GB01/02566 -26cyclopropyl; azacycloalkyl, such as piperidin-1-yl; oxazacycloalkyl, such as morpholino; and pyridyl, such as pyrid-3-yl. Further particular mention may be made of diazacycloalkyl, such as piperazin-1-yl; furyl, such as fur-2yl; thienyl, such as thien-2--yl; pyrrolidin-l-yl and pyrid-2yL.
Examples of values for G, are a bond, -CH 2 and CH 2 CH-i Examples of structures of groups comprising a 4,5,6,7tetrahydrobenzothienyl group as described above are: 0 N-CO H N WO 01/96305 PCT/GB01/02566 -27- Further examples of structures of groups comprising a 4,5,6,7-tetrahydrobenzothienyl group as described above are:
S
SV 0
ST^
0
N-CO
H
When R 3 is present as a substituent on the 1-position of a piperazinyl group, it is preferably hydrogen, (l-6C)alkanoyl, such as formyl, or (1-6C)alkoxycarbonyl, such as ethoxycarbonyl.
When R 3 is present as a substituent on a piperidin-l-yl group, it is preferably at the 3- or 4-position and is preferably hydrogen, (l-6C)alkyl, such as methyl; amido or (1- 6C)alkoxycarbonyl, such as ethoxycarbonyl.
When R 3 is present as a substituent at the 3-position of a 4,5,6,7-tetrahydrobenzothiophene group, it preferably represents a carboxy group; a (1-6C)alkoxycarbonyl group, such as methoxycarbonyl or ethoxycarbonyl; or a (1- 6C)alkylaminocarbonyl group, such as N-1,3dimethylbutylaminocarbonyl. Other examples of values for a (l-6C)alkylamincarbonyl group are methylaminocarbonyl and WO 01/96305 WO 0196305PCT/GB01/02566 -28iscbutylaminocarbonyl.
Accordingly, examples of particular values for Lp are: 3carboxy-4, 5,6, 7-tetrahydroberizothien-2-yl, 3-ethoxy-carbonyl- 4,5,6, 7-tetrahydrobenzothien-2-yl and 3-N- (2,3dimethylbutylaminocarbonyl-4, 5,6, 7-tetrahydrobenzothien-2-yl.
Further examples are 3-N-methylaminocarbonyl-4, 5,6,7tetrahydrobenzothien-2-yl and 3-N-isobutylaminocarbonyl- 4,5,6, 7-tetrahydrobenzothien-2-yl.
Further examples of R. when it is present as a substituent at the 3-position of a 4,5,6,7-tetrahydrobenzothiophene group are N,N-dialkylaminocarbonyl, such as dimethylarninocarbonyl or diethylaminocarbonyl; amido; (l-6C)alkoxycarbonyl, such a s methoxycarbonyl or ethoxycarbonyl; cyano arnd (1- GC)alkylsulfonyl, such as methylsulfonyl.
Accordingly, further examples cf Lp are 3-N,Ndimethylaminocarbonyl-4, 5,6, 7-tetrahydrobenzothien-2-yl, 3- 6,7-tetrahydrobenzothien-2-yl, 3ethoxycarbonyl-4 7-tetrahydrobenzothien-2-yl, 3-amido- 4,5,6, 7-tetrahydrobenzothien-2-yl, 3-methylsulfonyl-4, 5,6,7tetrahydrobenzothien-2-yl, 3-cyano-4,5,6,7tetrahydrobenzothien-2-yl and 3 -ethoxycarbonyl-4Hcyclopenta thienyl.
When R. is present as a substituent on a phenyl or pyridyl group, it is preferably a hydrogen atom.
Accordingly, examples of particular values for Lp are: 3benzyloxycarbonyl-4,5,6, 7-tetrahydrobenzothien-2-yl, 3benzylaminocarbonyl-4, 5,6, 7-tetrahydrobenzothien-2-yl, 3- (3pyridyl) methylaminocarbonyl-4, 5,6, 7-tetrahydro-benzothien-2yl, 3-cyclopropylmez~hylaminocarbonyl-4, 5,6,7tetrahydrobenzothien-2-yl, 3-morpholinocarbonyl-4,5, 6,7tetrahydrobenzothien-2-yl and 3-piperidinocarbonyl-4, 5,6,7tetrahydrobenzothien-2-yl. Further examples are: 3-piperazin- 1-ylcarbonyl-4, 5,6, 7-tetrahydrobenzothien-2-yl, 3- (4- 6,7-tetrahydrobenzothien-2yl, 3- (4-ethoxycarbonyl)piperazin-l-ylcarbonyl-4,5,6,7tetrahydrobenzothien-2-yl, 3- (4-methoxybenzyl) aminocarbonyl- 4,5,6, 7-tetrahydrobenzothieri-2-yl, 3- (4-ethoxycarbonyl) piperidin-1-ylcarbonyl-4, 5,6, 7-tetrahydrobenzothien-2-yl, 3- WO 01/96305 WO 0196305PCT/GB01/02566 -29- (3-amido) -piperidin-l-ylcarbonyl-4, 5,6, 7-tetrahydrobenzothien- 2-yl, 3-(4-amido) -piperidin-l-ylcarbonyl-4,5,6,7tetrahydrobenzothien-2-yl, 3-methylpiperidin-l-ylcarbonyl- 4,5,6, 7-tetrahydrobenzothien-2-yl, 3- (2-thienyl) carbonyl- 4,5,6, 7-tetrahydrobenzothien-2-yl, 3- (2-furylmethylaminocarbonyl-4,5,6,7-tetrahydrobenzothien-2-yl, 3- (1pyrrolidinyl) carbonyl-4, 5,6, 7-tetrahydrobenzothien-2-yl and 3- (2-pyridyl) 7-tetrahydrobenzothien-2-yl.
When R. is present as a substituent at the 4,5,6 and/or 7 position of a 4,5,6,7-tetrahydrobenzothien-2-yl group or the and/or 6 position of a 4H-cyclopenta)b)thienyl group, it is preferably a hydrogen atom or a (l-6C)alkyl group, such as methyl.
Examples of particlar values for Lp are accordingly 3ethoxycarbonyl-4-methyl-4, 5,6, 7-tetrahydrobenzothien-2-yl, 3ethoxycarbonyl-5-methyl-4, 5,6, 7-tetrahydrobenzothien-2-y1 and 3-ethoxycarbonyl-6-methyl-4, 5,6, 7-tetrahydrobenzothien-2-yl.
Another particular group of compounds of formula I is that in which L represents CONRId (such as CONH- or CONCH,) and Lp represents
R
3 y)
R
3 y S R3 R 3
Y
RSY
S/
in which RY is as defined hereinabove, X. is 0, S or NR, in which R. is independently selected from one of the values for R,,and is CH 2 or is as defined for Examples of particular values for R 3 Y are (1- 6C)alkoxycarbonyl, such as ethoxycarbonyl, N,Ndialkylaminocarbonyl, such as N,N-dimethylaminocarbonyl, and cyano.
R
3 is preferably hydrogen.
WO 01/96305 WO 0196305PCT/GB01/02566 R is preferably hydrogen, (1-6C) alkanoyl, amino(l- 6C)alkanofl or benzyloxycarbonyl. Examples of particular values for Rz are hydrogen, acetyl, amirioacetyl and benzyloxycarbonyi.
Accordingly, examples of particular values for Lp are: 3-ethoxycarbonyl-tetrahydro-4H-cyclohepta(b) thien-2-yl, 3pyranyl, 3ethoxycarbonyl-4, 5-dihydro-5H-thienc thiopyranyl, 3dimethylamido- 6-benzyloxycarbonyltetrahydrothieno [2,3blpyridin-2-yl, 3-dimethylamido-tetrahydrothieno [2,3blpyridin-2-yl, 3-dimethylamido-6-acetyltetrahydrothieno [2,3b~pyridin-2-yl, 3-dimethylamido-6-aminoacetyltetrahydrothieno- [2,3-blpyridin-2-yl, 3-dimethylamidc-G-methoxyacetyltetrahydrothieno pyridin-2-yl and 3-ethoxycarbonyltetrahydro-4,7-methanobenzo(b) thophen-2-yl.
The cyclic group attached to the alpha carbon is preferably cyclohexyl, piperidin-4-yl, 3, 4-methylenedioxyphenyl, fur-2-yl, thien-2-yl, thien-3-yl, imidazol-4-yl, oxazol-4-yl, oxazol-5-yl, thiazol-4-yl, thiazol-5-yl, pyrid-2yl, pyrid-3-yl, pyrid-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrazin-2-yl, pyrazin-3-yl, naphth-1-yl, naphth-2-yl, indol-5-yl, indan-5-yl, 3,4-dihydrobenzofur-5-yl, benzofur-2-yl or benzo[blthien-2-yl group, optionally substituted by R, or R 3 jXj in which X. is a bond, 0, NH- or CH, and R 3 j is phenyl optionally substituted by Ra.
Examples of particular values for R3. are:hydrogen; hydroxyl; for (l-6C)alkoxy: methoxy, ethoxy or isopropoxy; for (1-6C) alkyl: methyl, ethyl or isopropyl; for: (l-6C)alkanoyl: acetyl, propanoyl or isopropanoyl, for (l-6C)alkylaminoalkyl: methylaminomethyl or dimethylaminomethyl; for (1-60) hydroxyalkyl: hydroxymethyl carboxy; for (1-60) alkoxyalkyl: methoxymethyl; for (1-6C)aikoxycarbonyl: methoxycarbonyl or ethoxycarbonyl; WO 01/96305 WO 0196305PCT/GB01/02566 -31for (1-6C) alkylaminocarbonyl: methylaminocarbonyl or cimethylaminocarbonyl; for (1-6C) aminoalkyl: aminornethyl;
CONH-
2
CH
2
CON-
2 aminoacetyl; for (1-6C)alkanoylamino: formylamino or acetylamino; for hyciroxy (1-6C) alkanoylamino: hyciroxyacetylamino; for amino ,1-6C) alkanoylamino: aminoacetylamino; for (1-6C)alkylamino(1-6C)alkanoylamino: (1- 6C)alkylaminoacetyl, such as methylaminoacetyl; for di (1-Ge) alkylamino (1-6C) alkanoylamino: dimethylaminoacetyl amino; for (1-6e) alkoxycarbonylamino: methoxycarbonylamino, 1S ethoxycarbonylamino or t-butoxycarbonylamino; amino; for halo: fluoro or chioro; cyano; nitro; thiol; for (1-6e) alkyithic: methylthio; for (1-6C) alkylsuiphonyl: methylsuiphonyl or ethylsuiphonyl; for (1-Ge) alkylsuiphenyl: mnethylsuiphenyl; for irnidazolyl: imidazol-4-yl; hydrazido; for (1-6C) alkylimidazolyl: 2-methylimidazol-4-yl; for (1-Ge) alkylsuiphonanido: methylsuiphonylamido or ethylsuiphonylamido; for (1-Ge) alkylaminosulphonyi: methylaminosuiphonyl or ethylaminosuiphonyl; aminosuiphonyl; for (1-Ge) haloalkoxy: trifluorornethoxy; and for (1-6e) haloalkyl: trifluoromethyl.
An example of a particular value for is phenyl.
Examples of particular values for R 3 jXj are phenyl, phenoxy, phenylamino and benzyl.
WO 01/96305 WO 0196305PCT/GB01/02566 -32- Cy is preferably unsubstituted or substituted by one or two R3. groups.
Preferably R3a is hydrogen, hydroxyl, methyl, ethyl, isopropyl, acetyl, propanoyl, isopropanoyl, isopropoxy, amino, aminomethyl, hydroxymethyi, carboxy, amiclo, forinylamino, acetylamino, aminoacetyl or carboxy.
Examples of particular values for Cy are cyclohexyl, piperidin-4-yl, I-acetylpiperidin-4-yl, 1-propanoylpiperidin- 4-yl, 1-isobutyrylpiperidin-4-yl, 1-aminoacetylpiperidin-4-yiL, 5-methylfur-2-yl, imidazol-4-yl, 2-methylthiazol-4-yl, 2aminothiazol-4-yiL, 2-formylaminothiazol-4-yl, 2-aminothiazol- 2-formylaminothiazol-5-yl, 2-phenylthiazol-4-yl, 4aminopyrid-3-yl, 6-methylpyrid-2-y., 3-amino-pyrid-4-yl, naphth-l-yl, naphth-2-yl, benzofur-2-yl or 3-methylbenzothien- 2-yl. Further examples of particular values for Cy are 6aminopyrid-3-yl, 2-ethylthiazol-4-yl, 2-benzylthiazol-4-yl, 2methylsulforiamidothiazol-4-yl, 2-chloropyrid-3-yl, 2hydroxyacetylaminothiazol-4-yl, 2-N,N-dimethylaminoacetylaminothiazol-4-yl, indol-5-yl, indan-5-yl and 3,4dihydrobenzofur-2-yl.
In one group of compounds, the cyclic group attached to the alpha carbon is cycloalkyl (such as cyclohexyl), piperidinyl (such as piperidin-4-yl), 3,4-methylenedioxyphenyl, furyl (such as fur-2-yl), thienyl (such as thien-2-yl or thien-3-yl), imidazolyl (such as imidazol-4-yl), thiazolyl (such as thiazol-4-yl or thiazol-5-yl), pyridyl (such as pyrid-2-yl, pyrid-3-yl or pyrid-4-yl), naphthyl (such as naphth-1-yl or naphth-2-yl), benzofuryl (such as benzofur-2yl), benzo[bilthienyl (such as benzo[b]thien-2-yl) group, optionally substituted by R,,a or R~jXa in which Xi is a bond, 0, NH or CH 2 and is phenyl optionally substituted by Ra; and each R 3 a independently is hydrogen, hydroxyl, (1-6C) alkoxy, (1-6C) alkyl, (2-6C)alkenyl, (2-GC)alkynyl, (1-6C)alkanoyl, (1-6C) alkylaminoalkyl, hydroxy(l-6C)alkyl, carboxy, (1-6C) alkoxyalkyl, (l-6C) alkoxycarbonyl, (1-GC) alkylaminocarbonyl, aminoc(1-6C) alkyl CONK 2
CH
2
CONH
2 aminoacetyl, (1- 6C)alkanoylamino, (1-GC) alkoxycarbonylamino, amino, halo, WO 01/96305 WO 0196305PCT/GB01/02566 -33cyano, nitro, thiol, 1-6C) ailkyithic, (i-6C) alkyisulphoiyl, (1-6C) alkylsuiphenyl, imidazolyl, hydrazilo, (l-6C)alkylimidazolyl, (l-6C) alkylsuiphonamido, (1-6C) alkylaminosulphonyl, aminosuiphonyl, (1-6C) haloalkoxy, or (1- 6C) haloalkyl.
Within this group, examples of values for R 3 are hydrogen; hydroxyl; methoxy; ethoxy; isopropoxy; methyl; ethyl; isopropyl; acetyl; propanoyl; isopropanoyl; inethylaminomethyl; dimethylaminomethyl; hydroxyrnethyl; carboxy; rnethoxymethyl; methoxycarbonyl; ethoxycarbonyl; inethylaminocarbonyl; dimethylaminocarbonyl; aminomethyl;
CONH
2
CH
2
CONH
2 aminoacetyl; formylamino; acetylamino; methoxycarbonylamino; ethoxycarbonylamino; tbutoxycarbonylamino; amino; fluoro; chioro; cyano; nitro; thiol; methylthio; inethylsuiphonyl; ethylsuiphonyl; methylsuiphenyl; imidazol-4-yl; hydrazido; 2-methylimiclazol-4yl; methylsuiphionylamido; ethylsuiphonylamido; methylaminosuiphonyl; ethylaminosuiphonyl; aminosuiphonyl; trifluoromethoxy or trifluoromethyl; and
R
3 i X 1 is phenyl, phenoxy, phenylamino or benzyl.
Examples of values for Cy in this group are cyclohexyl, piperidin-4-yl, l-acetylpiperidin-4-yl, 1propanoylpiperidin-4-yl, l-isobutyrylpiperidin-4-yl, Iaminoacetylpiperidin-4 -yl, 3,4 -methyleriedioxyphenyl, methylfur-2-yl, iridazol-4-yl, 2-methylthiazol-4-yl, 2aminothiazol-4-yl, 2 -formylaminothiazol-4-yl, 2-aminothiazol- 2-f ormylaminothiazol-5-yiL, 2-phenylthiazol-4-yl, 4aminopyrid-3-yi, 6-methylpyrid-2-yl, 3-aminopyrid-4-yl, naphth-l-yl, naphth-2-yl, benzofur-2-yl and 3methylbenzothien-2-yl.
In another group of compounds, the cyclic group attached to the alpha carbon is an optionally R 3 .a substituted cycloalkyl (such as cyclohexyl), piperidinyl (such as piperidin-4-yl), thienyl (such as thien-2-yl or thien-3-yl), thiazolyl (such as thiazol-4-yl or thiazol-5-yl), pyridyl (such as pyrid-3-yl or pyrid-4-yl) or naphthyl (such as naphth-l-yl) group and each R 3 a independently is hydrogen, hydroxyl, (1-6C) alkoxy, (1-6C) WO 01/96305 WO 0196305PCT/GB01/02566 -34alkyl, (1-6C) alkylaminoalkyl, hydroxy(l-6C) alkyl, (1-6C) alkoxyalkyl, (1-60) alkoxycarbonyl, (1-6C) alkylaminocarbonyl, amino (1-6C) alkyl CONH,, CHCONH,, aminoacetyl, (1- 6C)alkanoyamino, (1-6C) alkoxycarbonylamino, amino, halo, cyano, nitro, thiol, (1-6C) alkylthio, (1-6C) alkylsuiphonyl, (1-6O) alkylsulphenyl, irnicazolyl, hydrazido, (1alkylimidazolyl, (1-6C) alkylsulphonamido, (1-6C) alkylaminosuiphonyl, aminosulphonyl, (1-GO) haloalkoxy, or (1- 6C) haloalkyl.
Within this group, examples of values for R~a are hydrogen, hydroxyl, methoxy, ethoxy, methyl, ethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl, methoxymethyl, methylaminocarbonyl, dimethylaminocarbonyl, aminornethyl, CONH 2
CH
2
CONH
2 aminoacetyl, formylamino, acetylamino, methoxycarbonylamino, ethoxycarbonylamino, tbutoxycarbonylanino, amino, fluoro, chioro, cyano, nitro, thiol, methylthio, methylsuiphenyl, imidazol-4-yl, hydrazi-do, 2-methylimidazol-4-yl, methylsuiphonylamido, ethylsuiphonylamido, methylaminosulphonyl, ethylaminosulphonyl, aminosuiphonyl, trifluoromethoxy and trifluoromethyl.
Examples of values for Cy in this group are cyclohexyl, piperidin-4-yl, 2-aminothiazol-4-yl, 2formylaminothiazol-4-yl, 2-aminothiazol-5-yl, 2- 4-aminopyrid-3-yl, 3-aminopyrid-4-yl and naphth-1-yl.
A group of compounds of particular interest is that in which Cy is a group of formula Rar b z in which one of Xa and Xb is N and the other is NH- or S, and each of R 3 r and is as defined for Compounds belonging to this sub-group have been found to show good bioavailability.
WO 01/96305 PCT/GB01/02566 Preferably Xa is S or NH and Xb is N. Particular mention may be made of compounds in which Xa is S and Xb is N.
Preferably R 3 is hydrogen.
Preferably Rr, is hydrogen, (l-6C)alkyl, amino, (1- 6C)alkanoylamino, hydroxy(l-6C)alkanoylamino, N,N-di(l- 6C)alkylaminoalkanoylamino, (1-6C)alkylsulfonylamino, phenyl or benzyl.
Another group of compounds in which good bioavailability has been found are compounds of formula I in which Cy is pyrid-2-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrazin-2-yl, pyrazin-3-yl or oxazol-4-yl, optionally substituted by R 3 a or 3x i The compounds of the invention may be prepared by conventional chemical synthetic routes, e.g. by amide bond formation to couple the aromatic function to the alpha atom and to couple the lipophilic function to the alpha atom. The cyclic group-alpha atom combination may conveniently derive from an alpha amino acid (preferably of D configuration) with the aromatic deriving from for example an acid derivative of a compound based on e.g. an aminomethylbenzoic acid (which is readily available). Amide formation from such reagents (in which any amino or hydroxyl function (especially in an aminomethyl group) may if desired be protected during some or all of the synthesis steps) yields a compound of formula R -CONH-CH(Cy)-COOH (V) (where R, represents
R
H
2 N R 6 and Cy is as defined above).
Prior to reaction the amino group in an aminoalkyl group should be protected by an appropriate protecting group, PG, e.g. Boc, Z, Fmoc or Bpoc. The use of protecting groups is described in McOmie, "Protective Groups in Organic Chemistry", Plenum, 1973 and Greene, "Protective Groups in Organic WO 01/96305 PCT/GB01/02566 -36- Synthesis", Wiley Interscience, 1981.
Compounds of formula are believed to be novel.
According to another aspect, therefore, the present invention provides a compound of formula
R
5 a Cy N HCOOH
H
PG'N R 6 a in which PG' represents hydrogen or an amino protecting group (PG) and Rs and are as defined hereinabove, or a salt thereof.
The lipophilic group may then conveniently be introduced by reaction of a compound of formula (or another analogous carboxylic acid) optionally after transformation into an activated form, e.g. an acid chloride or active ester, with a lipophilic group carrying or containing an amine group to produce a compound with the linkage of -CO- or -CO-NR ,(CH 2 )mfrom the alpha atom to the lipophilic group. The protecting group, PG, is then removed.
Alternatively a compound of formula V or another analogous carboxylic acid may be transformed into an alcohol by reaction with isobutylchloroformate and reduction with sodium borohydride.
Such an alcohol, e.g. of formula (VI)
R
2 CONH CH(Cy)CHOH (VI) can be reacted to introduce the lipophilic group by reactions such as: oxidation of the alcohol to form a corresponding aldehyde by oxidation with manganese dioxide or DMSO/oxalyl chloride or DMSO/SO, or Dess-Martin reagent) which may be reacted to introduce the lipophilic group by reactions such as: reaction with an organometallic, eg a Grignard reagent, optionally followed by oxidation of the resulting hydroxyl group with MnO,, DMSO/oxalyl chloride or Dess-Martin reagent.
WO 01/96305 PCT/GB01/02566 -37- In this way compounds with the linkage of -CO- between the alpha carbon and the lipophilic group may be produced.
An alternative route to these compounds is to carry out any of the above chemical reactions to incorporate the lipophilic group into a protected intermediate such as a compound of formula (VII).
PGN
COOH
H
PG Protecting group The protecting group may then be removed before coupling of the 3-aminomethylbenzoic acid (optionally protected).
The protection of amino and carboxylic acid groups is described in McOmie, Protecting Groups in Organic Chemistry, Plenum Press, NY, 1973, and Greene and Wuts, Protecting Groups in Organic Synthesis, 2nd. Ed., John Wiley Sons, NY, 1991.
Examples of carboxy protecting groups include Ci-C6 alkyl groups such as methyl, ethyl, t-butyl and t-amyl; aryl(C 1
C
4 )alkyl groups such as benzyl, 4-nitrobenzyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,4,6trimethoxybenzyl, 2,4,6-trimethylbenzyl, benzhydryl and trityl; silyl groups such as trimethylsilyl and tbutyldimethylsilyl; and allyl groups such as allyl and 1- (trimethylsilylmethyl)prop-l-en-3-yl.
Examples of amine protecting groups (PG) include acyl groups, such as groups of formula RCO in which R represents Ci-6 alkyl, C3- 10 cycloalkyl, phenyl C 1 -6 alkyl, phenyl, C 1 -6 alkoxy, phenyl C 1 -6 alkoxy, or a C3- 10 cycloalkoxy, wherein a phenyl group may be optionally substituted, for example by one or two of halogen, C 1
-C
4 alkyl and C 1
-C
4 alkoxy. Preferred amino protecting groups include t-butoxycarbonyl (Boc) and benzyl.
a-Amino acids of formula (VII) which are not commercially available can be synthesized by methods known in the art, for example as described in "Synthesis of Optically Active a-Amino Acids" by Robert M. Williams (Pergamon Press, 1989) and WO 01/96305 PCT/GB01/02566 -38- "Asymmetric Synthesis of ArylGlycines", Chem. Rev. 1992, 889- 917.
Compounds of the type (VII) made be prepared (for example) by one or more of the following methods.
from aryl or heteroaryl aldehydes via the Strecker synthesis or modifications thereof, via Bucherer-Bergs hydantoin synthesis, or via the Ugi methodology (Isonitrile Chemistry, Ugi I. Ed.; Academic: New York, 1971; pp145-199) with removal and replacement of protecting groups; (ii) from styrenes via Sharpless methodology Am. Chem.
Soc. 1998,120, 1207-1217) (iii) from aryl boronic acids via Petasis methodology (Tetrahedron, 1997, 53, 16463-16470) with removal and replacement of protecting groups; (iv) from aryl and heteroaryl acetic acids via Evan's azidation (Synthesis, 1997, 536-540) or by oximation, followed by reduction and addition of protecting groups; from existing aryl glycines by manipulation of functional groups, for example, alkylation of hydroxy groups, palladium assisted carbonylation of triflates derived from hydroxy groups and further manipulation of the carboxylic esters to give carboxylic acids by hydrolysis, carboxamides by activation of the carboxylic acid and coupling with amines, amines via Curtius reaction on the carboxylic acid; or (vi) from aliphatic, carbocylic and non-aromatic heterocyclic aldehydes and ketones using a Horner-Emmons reaction with Nbenzyloxycarbonyl)-a-phosphonoglycine trimethyl ester (Synthesis, 1992, 487-490).
Examples of synthetic schemes are shown below: WO 01/96305 WO 0196305PCT/GB01/02566 -39- Synthesis of protected 4-piperidyiglycine See Example 3 N7 oC 0 EtO.. P'O ~OEt ZNH 00 2M DBU, MeCN NBoc
L
ZNH CO 2 Me OH, THF, NBoc ZNH CO 2
H
EDO, HOAt
H
2 N-Lp NBoc I H ZNH N L 0
H
2 Pd/C, MeOH NBoc
H
HPN N Lp 0 Z is benzyloxycarbonyl Synthesis of protected 2-aniinothiazol-4ylglycine See Examples 4 and
NHCHO
S 1N 1. KHMDS, THF 2. Trisyl azicie, THF 3. AcOH, THF EtO 2
C
NHCHO
S )IN
N
3 DtO 2
C
H
2 PdIC, Boc 2
O
MeCH
NHCHO
S 111N NHBo EtO 2
C
LIOH, THF, H 2 0
NHCHO
S 11 N NHBoc H2C WO 01/96305 WO 0196305PCT/GB01/02566 Synthesis of Thiazole Lp groups R, 1. TFA, 0CM 0 C Cy CY H 2 NO N BocNH CO.H BcNH N! R2 NrC H I Y I 0 S 0 S/ -EDC BocNH 2 Synthesis of Alternative Thiazole Lp groups Senzthiazole synthesis from anilines 4-substituted H 2 N,6 isothiocyanate HHRIH N RH
I
I s S R =removable protecting group For 7-substitution
R
3 H HR R/H1- N H2 isotiliocyanate RHIY 3-' R/-f Hs R3R, R 3 R removable protecting group Cyclic aliphatic fused aminothiazoles
S
0 H kNHN
R
2 zH R \>NH Cl tLS Synthesis of Thiophene Lp Groups 0OBn0 0 O0
R
3 NH Cy ~Cy H~ N Y S A. N N N BocNH C0 2 H BocNH -Y i-i H s /n R BocNH Amides etc WO 01/96305 PCT/GB01/02566 -41- Alkyl/Aryl thiazolyl Glycines See Examples 12 13 and 26 2 J. Med- Chem. 1976. 16, 978 2 steps Et0 2 G literature 0 c' EtO 2 C benzene, heat
HO'N
R3ANH,
S
Et I Zn yl 1N formic acid HO'
IN
alkyl, phenyt or benzyl
S
0 1-S Lp, a N N
H
NH,
1. Boc 2 O, Et 3
N
2. LiOH, H20, TF jS Lp-NH 2 HOC N coupling conditions NHBoc Lp />R 3 TFA, C
N
NHBoc coupling conditions 0 TFA, DOM Lp.
V
0 BonN H H H N -I T
HZIN
Other heterocyclic Glyciies Using Ugi methodology See Examples 6 11 and 21 Example aldehyde synthesis (See Example 23) N 1. DiBal, THIF NH- Cl 2. sworn oxidation k Ci
CO
2 MO CHO OMe 0 Cy GO H NN N Cy+' CN-Lp methanol Lpy IC 0 CHO beet heat 6ecNH BocHN Mec Oe BocNHH 2NTFA, DCM, Et 3 SiH 0 Cy N
N,
HN NY 'Lp 9 0
H
2
N
WO 01/96305 WO 0196305PCT/GB01/02566 -42- Ug! Synthesis ror Lp groups with any Cy group Tetrahedron, 1999, 55, 7411 0 -N a, methanol heat CYCHO Il BocNH H 2
N
0 Cy
H
N- H NLp 0 BucHN MeC OMe j TA, EtSiH,
CM
o CyH
H
2
N
0 OMe SKOt~u
THF
Lp-NH 2 coupling conditions WO 01/96305 WO 0196305PCT/GB01/02566 -43- Synthesis of aminothiazolylglycine used for other 2-NH linked compoulnds See Examples 30 32 NH 2
NH,
S N Zn, HC0 2 H S N Boc 2 base Et0 2 0 OMe EtOC NH,
NHZ
S I,,N ZC 1, THF, NEt 3 S> NZ NHBoc NHBoc EtOC EtO 2
G
SNaCH, EtOH, heat
H
N, Lp
H
2 Pd/C
H
L
NHZ
S I,'N NHBoc
HOG
HO
2 NMe 2 0 or
HO
2 C 111OH or MeS0 2 Cl -44- Compounds of formula where Lp Is a tetrahydrobenzothlophene CN or AcOH, NH40Ac or R CN orheat, 4420 R e.g. CO2alkyl
R
CN X NR, 0, 8 R e.g. 2, 3, or 4 Me sulphur pyrdyl morpholilne S02alkyl EtOH SY or s Xz R3 1 .pybrop 1. TFA DCM 0 Cy SH Cy Cy A NH2 BocNH COH BoNH COH
R
3 BocHN BocHN EDC, DMAP Disclosed herein is a process for the preparation of a compound according to the invention which process comprises coupling a lipophilic group to a compound of formula (VIII)
R
2
(X)
2 -CH(Cy) -Z (VIII) or a protected derivative thereof (wherein X and Cy are as defined above and Z, is a reactive functional group).
Instead of introducing the group L-Lp as the final stage process step, the compounds of formula I may alternatively be prepared by a process in which the group R 2 is introduced in the final process step.
Also disclosed herein is a process for the preparation of a compound according to the invention which process comprises reacting a compound of formula (IX)
Z
2 -CH(Cy)-L-Lp
(IX)
(wherein Cy, L and Lp are as defined above and Z 2 is HX or a reactive functional group), or a protected derivative thereof, with a compound of formula (X)
R
2
Z
3
(X)
(wherein R 2 is as defined above and Z 3 is XH or an appropriate reactive group), or a protected derivative thereof, followed if necessary by the removal of any protecting groups.
Thus, for a compound of formula I in which X-X represents CONH, a compound of formula (IX) in which Z 2 is H 2 N may be reacted with a compounds of formula in which Z 3 is COOH or a reactive derivative thereof, such as an acyl halide or an anhydride, for example as described in the Examples herein.
:Further disclosed herein is a process for preparing a compound of formula I comprising deprotecting a compound of formula
R
2 '-X-X-CH -L-Lp wherein R 2 is R 2 (as hereinabove defined) or protected R 2 Cy' is Cy (as hereinabove defined) or protected Cy and Lp' is Lp (as hereinabove defined) or protected Lp; providing at least one protecting group is present.
Compounds of formula in which L represents CONH and X-X represents CONR a where R.ia is an optionally substituted benzyl group, such as 2,4-dimethoxybenzyl, may be prepared using Ugi methodology, starting from an aldehyde of formula CyCHO, an optionally substituted benzylamine of formula R,,,NH 2 a nitrile of formula NC-Lp and an N-protected 3aminomethylbenzoic acid, such as 3-BOC-aminomethylbenzoic acid. The protecting groups may be removed using trifluoroacetic acid. The procedure may be performed, for example, as described in Method 2 in the Experimental Section hereinafter.
If necessary physiologically tolerable salts can be formed using methods known in the art.
Where the lipophilic group Lp comprises more than one group, it may generally be formed by coupling these groups together at an appropriate stage in the preparation of the compound of formula I using conventional methods or as described in the Examples.
In a second aspect, the present invention provides a pharmaceutical composition which comprises a compound of the first aspect, together with at least one pharmaceutically acceptable carrier or excipient.
The compounds of the invention may be administered by any convenient route, e.g.
into the gastrointestinal tract rectally or orally), the nose, lungs, musculature or vasculature or transdermally. The compounds may be administered in any convenient io administrative form, e.g. tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g. diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents. Preferably the compositions will be sterile and in a solution or suspension form suitable for injection or infusion. Such compositions form a further aspect of the invention.
In a third aspect, the present invention provides a compound of the first aspect for use in therapy.
In a fourth aspect the present invention provides use of a compound of the first aspect for the manufacture of a medicament for treating a condition responsive to a tryptase inhibitor in a human or non-human animal.
In a fifth aspect the present invention provides a method for treatment of a condition responsive to a tryptase inhibitor said method comprising administration to a human or a non-human animal of a therapeutically effective amount of a compound of the first aspect, or a pharmaceutical composition of the second aspect.
In a sixth aspect the present invention provides a compound according to the first aspect, or a pharmaceutical composition of the second aspect when used for treating a condition responsive to a tryptase inhibitor.
The following are examples of pharmaceutical compositions of compounds according to the invention.
I R:\LIBH1S796.doc:LAM WO 01/96305 PCT/GB01/02566 -47- Formulation 1 Hard gelatin capsules are prepared using the following ingredients: Quantity (mg/capsule) Active Ingredient 250 Starch, dried 200 Magnesium stearate Total 460 mg The above ingredients are mixed and filled into hard gelatin capsules in 460 mg quantities.
WO 01/96305 PCT/GB01/02566 -48- Formulation 2 Tablets each containing 60 mg of active ingredient are made as follows: Active Ingredient 60 mg Starch 45 mg Microcrystalline cellulose 35 mg Polyvinylpyrrolidone 4 mg Sodium carboxymethyl starch 4.5 mg Magnesium stearate 0.5 mg Talc 1 mg Total 150 mg The active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S.
sieve. The granules so produced are dried at 50 0 C and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.
Viewed from this aspect the invention provides a pharmaceutical composition comprising a serine protease (tryptase) inhibitor according to the invention together with at least one pharmaceutically acceptable carrier or excipient.
The pharmaceutical composition may also optionally comprise at least one further anti-inflammatory agent.
Viewed from a further aspect the invention provides the use of a tryptase inhibitor according to the invention for the manufacture of a medicament for use in a method of treatment WO 01/96305 PCT/GB01/02566 -49of the human or non-human animal body a mammalian, avian or reptilian body) to combat treat or prevent) a condition responsive to said inhibitor, which comprises administering an effective amount of a compound according to the invention.
Viewed from a further aspect the invention provides a method of treatment of the human or non-human animal body a mammalian, avian or reptilian body) to combat a condition responsive to a tryptase inhibitor.
The dosage of the inhibitor compound of the invention will depend upon the nature and severity of the condition being treated, the administration route and the size and species of the patient. However in general, quantities of from 0.01 to 100 jmol/kg bodyweight will be administered.
All publications referred to herein are hereby incorporated by reference.
The invention will now be described further with reference to the following non-limiting Examples.
WO 01/96305 PCT/GB01/02566 Experimental: Abbreviations used follow IUPAC-IUB nomenclature. Additional abbreviations are BOC, t-butyloxycarbonyl; HPLC, high performance liquid chromatography; LC, liquid chromatography; MS, mass spectrometry; Rt, retention time; NMR, nuclear magnetic resonance; DMF, dimethylformamide; Quant, quantitative; DMAP, dimethylaminopyridine; TFA, trifluoroacetic acid; Sat., saturated; Aq., aqueous; DCM, dichloromethane; PyBroP, bromo-tris-pyrrolidino-phosphonium hexafluorophosphate; Phg, phenylglycine; Chex, cyclohexyl; THF, tetrahydrofuran; DiBal, diisobutylaluminium hydride; KHMDS, potassium bis(trimethylsilyl)amide; Trisyl, triisopropylbenzenesulphonyl; Z, benzyloxycarbonyl; and EDC, 1- (3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.
Starting materials were purchased from Aldrich (Gillingham, UK), Lancaster (Morecambe, UK), Avocado (Heysham, UK), Maybridge (Tintagel, UK), Nova Biochem (Nottingham, UK) or Bachem.
Purification: Flash column chromatography was carried out using Merck silica gel Si60 (40-63 tm, 230-400 mesh). Purification of final products was by crystallisation, flash column chromatography or gradient reverse phase HPLC on a Waters Deltaprep 4000 at a flow rate of 50 mL/minute using a Deltapak C18 radial compression column (40 mm x 210 mm, 10-15 mm particle size).
Eluant A consisted of aqueous trifluoroacetic acid (0.1 and eluant B 90% acetonitrile in aqueous trifluoroacetic acid (0.1 with gradient elution (Gradient, 0 minutes 5 B for 1 minutes, then 5 B to 20 B over 4 minutes, then 20 B to B over 32 minutes). Fractions were analysed by analytical HPLC and LC/MS before pooling those with >95 purity for lyophilisation.
WO 01/96305 PCT/GB01/02566 -51- Analysis: Proton nuclear magnetic resonance (1H NMR) spectra were recorded on a Bruker DPX300 (300 MHz). Analytical HPLC's were performed on a Shimadzu LC6 gradient system equipped with an autosampler. Eluant A consisted of aqueous trifluoroacetic acid (0.1 and eluant B consisted of 90 acetonitrile and water, containing trifluoroacetic acid (0.1 Gradient 1 elution began at 5 B and increased to 100 B over seven minutes. Gradient 2 elution began at 5 B and increased to 100 B over ten minutes. Gradient 3 elution began at 5 B for one minute, increasing to 20 B after the fourth minute, B after the 1 4 t h minute and then 100 B after the 1 5 t h minute. The columns used were Luna 2 C18 (3 p, 30 mm x 4.6 mm), Luna 2 C18 (5 t, 150 mm x 2 mm) and a Symmetry Rp8 (3.5 p, 50 x 2.1 mm).
LC/MS were performed on a PESCIEX single quadrupole API-150EX instrument, equipped with a Luna 2 C18 column (3 i, 30 mm x 4.6 mm) eluting with 20 to 100 acetonitrile in water over five minutes (gradient 4).
Method 1 3-(Aminomethyl)benzoyl-D-phenylglycine 2-aminobenzothiazol-6amide bis(trifluoroacetate) salt.
2,6-Diaminobenzothiazole 2-Amino-6-nitrobenzothiazole (500 mg, 2.56 mmol) was dissolved in methanol (20 mL) and 10 palladium on carbon (50 mg) was added as a slurry in methanol (1 mL). The atmosphere was replaced with hydrogen and the suspension was stirred overnight. The catalyst was removed by suction filtration and the solvent evaporated to afford 2,6-diaminobenzothiazole (420 mg, 99 as a pale yellow solid.
N-BOC-D-Phenylglycine 2-aminobenzothiazol-6-amide WO 01/96305 WO 0196305PCT/GB01/02566 -52- N-BOC-D-Phenylglycine (250 mg, 1.0 rnmol), i-(3dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (190 mg, 1.0 inmol) and 7-aza-1-hydroxybenzotriazole (140 mg, mmcl) were stirred in dirnethylformamide (3 mL) for ten minutes. 2,6-Diaminobenzothiazole (160 mg, 1.0 mmol) was then added and the solution was stirred overnight at room temperature. Ethyl acetate (15 mL) was added and the solution was washed with water (5 mL), saturated citric acid solution mL) saturated NaHCO 3 (5 mL) and water ml) and dried over MgSO 4 The solvent was removed under reduced pressure to afford N-BOC--D-phenylglycine 2-arninobenzothiazol-6-amide.
1'H NMR (CDCl 3 8.93 (1 H, br s, C(O)NHAr); 7.72 (1 H, s, benzothiazole 7.35 (2 H, br s. Ph); 7.23 7.05 (3 H, m, Ph); 6.93 (1 H, d, J 10 Hz, benzothiazole C(4)H or 6.72 (1 H, d, J 10 Hz, benzothiazole C(4)H or C H) 6. 05 (1 H, d, J 7 Hz, CHPh) 5. 92 (2 H, br s, NH 2 45 (1 H, br s, BOCNH) 1. 27 (9 H, s, t~u) D-Phenylglycine 2-aaninobenzothiazol-6-amide A solution of N-BOC-D--phenylglycine 2-aminobenzothiazol-6amide in dichioromethane (5 mL) was treated with trifluoroacetic acid (5 mL) and stirred for 30 minutes. The dichioromethane and excess trifluoroacetic acid were removed under reduced pressure and the residue was triturated with diethyl ether to afford D-phenylglycine 2-aminobenzothiazol-6amide as its trifluoroacetate salt (350 mg, 89 3- (Aminomethyl)benzoyl-D-phenylglycine 2-aminobenzothiazol-6amnide trifluoroacetate salt N-BOC--3-aminomerihylbenzoic acid (250 mg, 1.0 mmcl), l-(3dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (190 mg, 1.0 mmcl) and 7-aza-l-hydroxybenzotriazole (140 mg, mmcl) were stirred in dimethylformamide (10 mL) for five minutes. D-Phenylglycine 2-amincbenzothiazol-6-amide WO 01/96305 PCT/GB01/02566 -53trifluoroacetate salt (350 mg, 0.85 mmol) was then added and the mixture was stirred overnight. The solution was poured into ethyl acetate (20 mL) and washed with 5 HC1 (5 mL), saturated NaHC03 (5 mL) and water (5 mL), dried over MgS04 and the solvent removed under reduced pressure. The crude product was purified by flash column chromatography on silica gel ethyl acetate 40 hexane to 100 ethyl acetate) to afford -3-(N-BOC-aminomethyl)benzoyl-D-phenylglycine 2aminobenzothiazol-6-amide. This was dissolved in dichloromethane (5 mL) and trifluorcacetic acid (5 mL) was added. The solution was stirred at room temperature for minutes before the dichloromethane and excess trifluoroacetic acid were removed under reduced pressure. The residue was triturated with diethyl ether to afford 3- (aminomethyl)benzoyl-D-phenylglycine 2-aminobenzothiazol-6amide as its trifluoroacetate salt (150 mg, 32 1 H NMR (d 4 MeOH): 8.21 ppm (1 H, s, benzothiazole 7.97 (1 H, s, aminomethylbenzoyl 7.94 (1 H, d, J 5 Hz, 3- (aminomethyl)benzoyl 7.80 7.48 (5 H, m, Ar); 7.47 7.32 (4 H, m, Ar); 5.81 (1 H, s, CHPh); 4.22 (2 H, s, CH 2
NH
2 HPLC (Luna 2, Gradient rt 2.80 minutes.
LC/MS (Luna 2, Gradient rt 1.40 minutes, 432 (MH) Examples 1 5 were synthesised in the same way as the compound of Method 1 using the indicated amino acid in place of phenylglycine and the indicated amine in place of 2,6diaminobenzothiazole.
Example 1 3-(Aminomethyl)benzoyl-D-cyclohexylglycine trifluoroacetate salt.
WO 01/96305 WO 0196305PCT/GB01/02566 -54- Prepared from N-BOC-D-cyClohexylgiycine and 1H NMR (d 4 MeCH): 7. 88 7. 02 ppm (7 H, mn, Ar); 4. 43 (1 H, d, J =9 Hz, CH (cHex)l 4. 04 (2 H, s, CH 2
NH
2 2. 78 68 (4 H, in, indane C E 2 and C H 2 2. 04 1. 82 (4 H, mn, indane C H 2 cHex CH 2 1. 77 1. 56 (4 H, mn, 2 x cHex CH 2 1. 36 0. 95 H, m, 2 x cHex CH 2 and CR) HPLC (Luna 2, Gradient rt 4.27 minutes.
LCMS (Luna 2, Gradient rt 2.21 minutes, 406 (MH) t Example 2 3- (Aminomethy1) benzoyl-D/L-1-naphthylglyciLne trifluoroacetate salt.
Prepared from N-BOC-D/L-1-naphthylglycine and I H NMR (d4 MeCH) 8. 25 ppm (1 H, d, J 7. 2 H z, Ar) 8. 04 7.84 (4 H, m Ar); 7.75 7.44 (7 H, m, Ar); 7.33 (1 H, d, J 7.25 Hz, Ar); 7.16 (1 H, d, J 7.25 Hz, Ar); 6.72 (1 H, s, CHAr) 4. 15 (2 H, s, CH 2
NH
2 2. 94 2. 78 (4 H, m, indane C H 2 C H 2 2. 17 1. 98 (2 H, m, indane C H 2 HPLC (Luna 2, Gradient 1) rt 4.37 minutes.
LCMS (Luna 2, Gradient rt 2.37 minutes, 450 Example 3 3- (Aminomethyl) benzoyl-D/L-piperidin-4-ylglycine bis (trifluoroacetate) salt.
(M-BOC-PiperiLdin-4-ylidene) -(N-benzyloxycarbonyl) glycine methyl ester N-BOC-4-Piperidone (2.0 g, 10 inmol), N-(benzyloxycarbony)-oc- WO 01/96305 PCT/GB01/02566 phosphonoglycine trimethyl ester (3.64 g, 2.20 mmol) and 1,8diazabicyclo[5.4.0]undec-7-ene (1.57 mL, 2.10 mmol) were stirred in acetonitrile overnight. The solvent was removed and the residue taken up in ethyl acetate (50 mL) and washed with water (2 x 10 mL), dried (MgSO 4 and evaporated under reduced pressure. The residual oil was purified by chromatography on silica gel (ethyl acetate hexane, 40 to afford the unsaturated ester (3.63 g, 90 H NMR (CDCl 3 7.36 ppm (5 H, br s, Ph); 6.05 (1 H, br s, NH); 5.12 (2 H, s, CH 2 Ph); 3.73 (3 H, br s, OMe); 3.50 (4 H, br s, piperidine C(2)H 2 and C(6)H 2 2.86 (2 H, br s, piperidine C(3)
H
2 or C(5) H2); 2.45 2.36 (2 H, m, piperidine C(3) H 2 or
H
2 1.47 (9 H, s, tBu).
(N-BOC-Piperidin-4-ylidene)-(N-benzyloxycarbonyl)glycine A solution of the methyl ester (391 mg, 1 mmol) in tetrahydrofuran (10 mL) was treated with 1 M LiOH (2 mL, 2 mmol) and heated at reflux for 4 hours. The solvent was removed under reduced pressure and the residue diluted with water (20 mL). The aqueous solution was acidified to pH 4 with aqueous HC1 and extracted with ethyl acetate (3 x 20 mL).
The combined organic extracts were dried (MgSO 4 and concentrated under reduced pressure to afford the acid as a brown solid (305 mg, 78 which was carried forward without further purification.
(N-BOC-Piperidin-4-ylidene)-(N-benzyloxycarbonyl)glycine A solution of the acid (253 mg, 0.65 mmol) in dimethylformamide (20 mL) was treated with 1-(3dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (124 mg, 0.65 mmol), l-hydroxy-7-azabenzotriazole (88 mg, 0.65 mmol), 5-aminoindane (86 mg, 0.65 mmol) and 4-(N,Ndimethylamino)pyridine (10 mg) and stirred overnight at room WO 01/96305 PCT/GB01/02566 -56temperature. The solution was partitioned between ethyl acetate (30 mL) and water (30 mL), separated, and the organic phase was washed with 5 aqueous HC1 (30 mL), saturated aqueous NaHCO 3 (30 mL) and water (30 mL), dried (MgSO4) and concentrated under reduced pressure to afford a colourless solid. The crude product was purified by flash chromatography (ethyl acetate hexane 1 1) to afford the indanamide as a colourless solid (215 mg, 65 H NMR (CDC1 3 8.31 (1 H, br s, NH); 7.43 (9 H, m, 8 Ar, NH); 5.01 (2 H, s, CH 2 Ph); 3.34 (4 H, br s, piperidine C(2)H 2 and C(6)H 2 2.83 2.71 (4 H, m, indane C(1)H 2 and C(3)H 2 2.54 (2 H, br s, piperidine C(3)H 2 or C(5)H 2 2.23 2.14 (2 H, m, piperidine C(3)H 2 or C(5)H 2 2.05 1.92 (2 H, m, indane C(2)H 2 1.38 (9 H, s, tBu).
D/L-(N-BOC-Piperidin-4-yl)glycine Palladium on carbon (50 mg) was added to a solution of the alkene (215 mg, 0.43 mmol) in ethanol (20 mL) and the suspension was stirred under a hydrogen atmosphere overnight.
The mixture was filtered and the filtrand was washed with ethanol (20 ml) before the combined solvents were concentrated under reduced pressure to afford the deprotected saturated amine as a colourless oil (97 mg, 60 The crude amine was carried forward without further purification.
The remaining steps of the synthesis are identical to those of the compound in method 1.
3-(Aminomethyl)benzoyl-D/L-piperidin-4-ylglycine bis(trifluoroacetate) salt.
H NMR (d 4 MeOH): 8.04 7.92 ppm (2 H, m, Ar); 7.73 7.55 (2 H, m, Ar); 7.49 (1 H, s, Ar); 7.32 (1 H, d, J= 7.2 Hz, Ar); 7.18 (1 H, d, J 7.2 Hz, Ar); 4.68 (1 H, d, J 9 Hz, CH(Pip)); 4.21 (2 H, s, CH 2
NH
2 3.54 3.40 (2 H, m, WO 01/96305 PCT/GB01/02566 -57piperidine C(2)H and 3.13 2.96 (2 H, m, piperidine C(2)H and 2.94 2.81 (4 H, m, indane C(1)H 2 and C(3)H 2 2.41 2.23 (1 H, m, piperidine 2.20 1.95 (4 H, m, indane C(2)H 2 piperidine C(3)H and 1.84 1.60 (2 H, m, piperidine C(3)H and C(4)H).
HPLC (Luna 2, Gradient rt 3.08 minutes.
LCMS (Luna 2, Gradient rt 1.27 minutes, 407 (MH) Example 4 3-(Aminomethyl)benzoyl-D/L-2-(N-formylamino)thiazol-4yl]glycine 5-indanamide trifluoroacetate salt Prepared from D/L-a-(N-tbutyloxycarbonyl)-[2-(Nformylamino)thiaz-4-yl]glycine (synthesised as described below) and Ethyl a-azido-[2-(N-formylamino)thiaz-4-yl]acetate A solution of ethyl [2-(N-formylamino)thiaz-4-yl]acetate (1 g, 0.0047 mol) in THF (10 mL) was stirred under argon at -78 0 C and potassium bis(trimethylsilyl)amide (2.8 g, 0.014 mol) in THF mL) was added. After stirring for 30 minutes, 2,4,6triisopropylbenzenesulfonyl azide (3.6 g, 0.012 mol) was added as a solid in one portion. After 5 minutes, acetic acid (1.4 mL, 0.018 mol) was added and the mixture warmed to room temperature. The reaction mixture was then partitioned between ethyl acetate (100 mL) and water (100 mL), separated and the organic layer dried (MgSO 4 Evaporation of the solvent and purification of the residue by silica gel chromotography afforded the azide (0.95 g, 80 1H NMR (CDCl 3 8.78 ppm (1 H, s, NHCHO); 6.98 (1 H, s, 5.95 (1 H, s, CHN 3 4.18 (2 H, m, CH 2
CH
3 1.20 (3 H, m,
CH
2
CH
3 WO 01/96305 PCT/GB01/02566 -58- Ethyl a- butyloxycarbonylamino) [2-(N-formylamino)thiaz-4yl]acetate Di-tbutyl dicarbonate (0.9 g, 0.004 mol) and 5% palladium on carbon (catalytic amount) were added to a solution of the azide (0.95 g, 0.0037 mol) in methanol (25 mL). The mixture was stirred at room temperature under an atmosphere of hydrogen for 8 hours. After this time the mixture was filtered through celite, washing through with methanol (25 mL).
Evaporation of the solvent and purification of the residue by silica gel chromotography afforded the tbutyloxycarbonyl amine as a pale oily solid (1.1 g, 90 IH NMR (CDC13): 8.53 ppm (1 H, s, NHCHO); 6.89 (1 H, s, 6.18 (1 H, d, J 8 Hz, NHBoc); 5.38 (1 H, d, J 8 Hz, CHN); 4.06 (2 H, m, CH 2
CH
3 1.28 (9 H, s, tBu); 1.12 (3 H, m,
CH
2
CH
3 D/L-a-Nt butyloxycarbonyl-[2-(N-formylamino)thiaz-4-yl]glycine A solution of the ester (1.1 g, 0.0031 g) in THF (25 mL) was treated with 1 M aqueous LiOH (5 ml, 0.005 mol) and heated at reflux for 1 hour. The solvent was removed under reduced pressure and the residue diluted with water (100 mL). The pH was reduced to 2 using 5% aqueous HCI and the aqueous phase was extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were dried (MgSO 4 and concentrated under reduced pressure to afford the acid as a white solid (0.8 g, 84 IH NMR (d 4 MeOH): 8.38 ppm (1 H, s, NHCHO); 7.01(1 H, s, 5.21 (1 H, s, CHN); 1.39 (9 H, s, tBu).
3-(Aminomethyl)benzoyl-D/L-[2-(formylamino)thiazol-4yl]glycine 5-indanamide trifluoroacetate salt 1 H NMR (d 4 MeOH): 10.10 ppm (1 H, s, NHCHO); 8.80 (1 H, d, J 8 Hz, NH); 8.48 (1 H, s, NHCHO); 7.97 (2 H, br s, Ar); 7.58 (2 H, m, Ar); 7.42 (1 H, s, aminothiazole 7.37 (1 H, d, J 7 Hz, indane 7.18 (1 H, s, indane 7.10 (1 H, WO 01/96305 WO 0196305PCT/GB01/02566 -59d, J 7Hz, indane, 5.92 (1 H, m, CHAr); 4.18 (2 H,s,
CH
2
NH
2 2. 83 (4 H, m, indane C H 2 and C H 2 2. 02 (2 H, mn, indane C H 2 HPLC (Luna 2, gradient rt =3.71 minutes.
LC/MS (Luna 2, gradient rt 2.05 minutes; 450 Example 3- (Amiriomethyl) benzoyl-D/L-2-aininothiazol-4-ylglycine-5indanaiuide bis (hydrochloride) salt.
Prepared from D/L-cx--Nt butyloxycarbonyl--[2- (Nformylamino)thiaz-4-y1]glycine and synthesised using the method of Example 4 except that the final deprotection was effected using 3 N aqueous HC1 in THF, in order to remove both the tbutylcxycarbonyl and forinyl protecting groups.
'H NMR (d 4 MeOH): 7. 87 ppm (2 H, mn, Ar) 7. 51 (1 H, m, Ar); 7.48 (1 H, t, J= 7 Hz, (aminomethyl)benzoyl 7.40 (1 HI, s, aminothiazole C H) 7.20 (1 H, d, J 8 Hz, indane 7.05 (1 H, d, J 8 Hz, indane 6.73 (1 H, s, indane, C H) 5. 78 (1 H, s, CHAr); 4. 12 (2 H, s, CH 2
NH
2 2. 79 (4 H, m, indane C (1)H 2 and C H 2 2. 00 (2 H, m, indane C H 2 HPLC (Luna 2, gradient rt =3.21 minutes.
LC/MS (Luna 2, gradient rt =1.78 minutes; 422 Method 2 3- (Aminomethyl) benzoyl-D/L-4-methylphenylglycine hydrochloride salt.
To a solution of 5-amninoindane (7.53 g, 56.5 inmol) in DMF (100 mL) was added formic acid (2.2 mL, 58.3 mnol), 1-(3diiethylaminopropyl) -3-ethylcarbodlimide hydrochloride (10.94 g, 57 mmcl) and diisopropylethylamine (19.7 mL, 0.11 mol). The resulting solution was stirred overnight and then partitioned between saturated aqueous citric acid (100 mL) and ethyl WO 01/96305 PCT/GB01/02566 acetate (200 mL). The organic layer was separated and washed with aqueous sodium bicarbonate solution (100 mL) and water (3 x 100 mL), then concentrated under reduced pressure to give the formamide as a thick oily solid (8.5 g, 93 To a solution of N-formyl-5-aminoindane (12 g, 74.5 mmol) in dichloromethane (100 mL) was added triethylamine (23 mL, 0.17 mol) and the solution was cooled to 0°C under nitrogen.
Phosphorous oxychloride (7 mL, 75 mmol) was added dropwise over 10 minutes, keeping the temperature at 0°C. The mixture was stirred at this temperature for 1 hour. A solution of sodium carbonate (15.6 g, 0.18 mol) in water (50 mL) was then added dropwise, keeping the temperature below 30 0 C. The mixture was diluted with water (100 mL) and then separated.
The aqueous layer was extracted with dichloromethane (2 x mL) and the combined organic extracts then washed with brine (200 mL), dried over magnesium sulphate and concentrated under reduced pressure. The crude oil was purified by vacuum distillation to give the product as a clear oil which solidified at low temperature (7.8 g, 72 bp. 100-105°C (0.05mBar).
1 H NMR (CDC1 3 7.10 (4 H, m, Ar); 2.82 (4 H, t, J 8 Hz, C(1)H 2 C(3)H 2 2.03 (2 H, quintet, J 8 Hz, C(2)H 2 3-(BOC-aminomethyl)benzoyl-D/L-N-(2,4-dimethoxybenzyl)-4methylphenylglycine A solution of p-tolualdehyde (168 mg, 1.4 mmol) and 2,4dimethoxybenzylamine (207 pL, 230 mg, 1.4 mmol) in dichloremethane (1 mL) was allowed to stand overnight. The solution was diluted to 5 mL with dichloromethane and dried over magnesium sulfate. The solvent was decanted off, the solids rinsed with dichloromethane (2 x 1 mL) and the solution WO 01/96305 PCT/GB01/02566 diluted further to 10 mL. 3-(N-BOC-aminomethyl)benzoic acid (350 mg, 1.4 mmol) and indane-5-isonitrile (4 mL of a 5 g/100 mL solution in dichloromethane, 200 mg, 1.4 mmol) were added.
The solution was stirred under argon for 14 days before being evaporated under reduced pressure onto silica gel (5 g).
Purification by Bio-age Flash 40 chromatography, eluting with 2:1 to 1:1 hexane:ethyl acetate afforded 3-(BOCaminomethyl)benzoyl-D/L-N-(2,4-dimethoxybenzyl)-4methylphenylglycine indan-5-amide as a white foamy solid (297 mg, 32 3-(Aminomethyl)benzoyl-D/L-4-methylphenylglycine hydrochloride salt.
A solution of 3-(BOC-aminomethyl)benzoyl-D/L-N-(2,4dimethoxybenzyl)-4-methylphenylglycine indan-5-amide (290 mg, 0.43 mmol) in dichloromethane (3 mL) was stirred at room temperature and trifluoroacetic acid (3 mL) was added. After minutes the excess trifluoroacetic acid and dichloromethane were removed under reduced pressure. The purple oily residue was taken up in methanol (2 mL) and purified by SCX acid ionexchange chromatography, eluting with methanol and then 5% 2 N NH 3 /methanol in dichloromethane, to afford 3- (aminomethyl)benzoyl-D/L-4-methylphenylglycine as its free base. This was taken up in acetonitrile (5 mL) and water (10 mL) was added, followed by 5 HC1 to afford a pale yellow solution. The acetonitrile was removed under reduced pressure and the aqueous solution was lyophilised to afford 3-(aminomethyl)benzoyl-D/L-4methylphenylglycine indan-5-amide as its hydrochloride salt (92 mg, 0.20 mmol, 48 'H NMR (CD 3 CN): 8.47 ppm (1 H, br s, Ar); 7.72 (1 H, s, Ar); 7.67 7.53 (2 H, m, Ar); 7.46 7.28 (4 H, m, Ar); 7.13 (2 H, d, J 10 Hz, tolyl C(2)H's or 7.07 (1 H, d, J WO 01/96305 WO 0196305PCT/GB01/02566 -62- Hz, indane C(6)H or 5.55 (1 H, s, CHTol); 3.74 (2 H, S, CH 2
NH
2 2. 81 (2 H, t, J 6 Hz, indarie C H 2 or C H 2 2. 77 (2 H, t, LJ= 6 Hz, indane C H 2 or C H 2 2. 27 (3 H, s,
CH
3 Ar) 2. 10 1. 95 (2 H, m, indane C H 2 HPLC (Luna 2, Gradient rt =4.53 min.
LC/MS (Luna 2, Gradient rt =2.13 main, 414 Examples 6 11 were synthesised in the same way as the compound of method 2 using thte indicated aldehyde.
Example 6 3- (.minomethyl) benzoyl-D/L-6-methylpyridin-2-ylglycine indanbis(hydrochloride) salt.
From 6-methylpyridine-2-carboxaldehyde.
1 H NMR (Free base, ODC1 3 9.70 ppm (1 H, br s, NH-Indane); 8.27 (1 H, d, J 7 Hz, NH-CHAr); 7.97 (1 H, s, Ar); 7.89 (1 H, d, J 9 Hz, Ar); 7.67 7.48 (4 H, ma, Ar); 7.27 7.10 (4 H, ma, Ar) 5. 85 (1 H, d, J 7 Hz, CHPy) 4. 00 (2 H, s, CH 2
NH
2 2. 90 (2 H, t, JT= 7 Hz, indane C (1)-H2 or C H 2 2. 88 (2 H, t, J 7 Hz, inclane C H 2 or C 2. 66 (3 H, s, CH 3 Py) 2. 09 (2 H, quintet, J 7 Hz, indane C H 2 1. 64 (2 H, br s, NH 2 HPLC (Luna 2, Gradient rt =3.28 rain.
LC/MS (Luna 2, Gradient rt =2.05 rain, 415 Example 7 3- (Aminomethyl) benzoyl-D/L-imidazol-4-ylglycine bis (hydrochloride) salt.
From imidazole-4-carboxaldehyde.
1h NMR (Free base, CDCl 3 9. 90 ppm (1 H, br 3, NH-Indane); 8.39 (1 H, br s, NH); 7.83 (1 H, s, Ar); 7.72 (1 H, d, J= 9 Hz, Ar); 7.40 (2 H, d, J 10 Hz, Ar); 7.36 7.25 (2 H, ma, WO 01/96305 WO 0196305PCT/GB01/02566 Ar); 7.24 (1 H, d, J 8 Hz, indane C(6)H or 7.04 (1 H, d, J 8 Hz, indane C(6)H or 6.93 (1 H, s, Ar); 6.02 (1 H, br d, J 5 Hz, CR-Tm) 3.78 (2 H, s, CH 2
NH
2 2. (2 H, t, J 7 Hz, indane C H 2 or C H 2 2 .7 8 (2 H, t, J= 7 Hz,. indane C H 2 or C H 2 2. 00 (2 H, quintet, J 7 Hz, indane 0(2)H 2 HPLC (Luna 2, Gradient rt =3.65 min.
LC/MS (Luna 2, Gradient rt =1.45 min, 390 (MH) Example 8 3- (Aminomethy1) benzoyl-D/L- hydrochloride salt.
From piperonal.
1H NMR (Free base, CDC1 3 9.32 ppm (1 H, br s, NH) 7. 97 (1 H, di, J 9 Hz, Ar); 7.79 (1 H, s, Ar); 7.75 (1 H, di, J 10 Hz, Ar); 7.47 (1 H, di, J 8 Hz, Ar); 7.41 7.30 (2 H, mn, Ar); 7. 08 6. 98 (2 H, m, Ar) 6. 68 (1 H, di, LT 10 H z, Ar) 6. 16 (1 H, d, J 8 Hz, CH-Np) 5.85 (2 H, d, J 11 Hz, OCH 2 O) 3. 84 (2 H, S, CH 2
NH
2 2. 80 (2 H, t, J 7 Hz, indane C H2 or C H 2 2. 76 (2 H, t, J 7 Hz, indane C H 2 or C H 2 2.0 0 (2 H, quintet, J 7 Hz, indane C H 2 1.-8 5 (2 H, br s, NH 2 HPLC (Luna 2, Gradient rt =2.59 min.
LC/MS (Luna 2, Gradient rt =2.13 min, 444 Example 9 3- (Aminomethyl) benzoyl-D/L-5-uethylfuran-2-ylglycine amide hydrochloride salt.
From 5-methylfuran-2-carboxaldehyde.
1 H NMR (Free base, CDC1 3 9. 02 ppm (1 H, br s, NH) 7. 78 (2 H, br s, NH and Ar); 7.65 (1 H, di, J 9 Hz, Ar); 7.39 (1 H, s, Ar); 7.37 (1 H, di, J 8 Hz, Ar); 7.28 (1 H, t, J 7 Hz, 3- WO 01/96305 WO 0196305PCT/GB01/02566 aminomethyiphenyl 7.19 (1 H, d, J 10 Hz, Ar); 7.00 (1 H, di, J 9 Hz, indane C(6)H or 6.29 (1 H, d, J =3 Hz, furyl C(3)H or 6.15 (1 H, d, J 8 Hz, CH-Fur); 5.79 (1 H, di, J 3 Hz, furyl C(3)H or 3.82 (2 H, s,
CH
2
NH
2 2. 75 (2 H, t, J 7 Hz, indane C H 2 or C H 2 2. 72 (2 H, t, J 7 Hz, indane C H 2 or C H 2 2. 40 (2 H, br s,
NH
2 2. 10 (3 H, S, CH 3 -Fur) 1. 93 (2 H, quintet, LJ= 7 Hz, indane 0(2()H 2 HPLC (Luna 2, Gradient rt =4.09 min.
LC/MS (Luna 2, Gradient rt =2.05 min, 404 Example 3- (Aminomethyl) benzoyl-D/L-benzofuran-2-ylglycine amide hydrochloride salt.
From benzo-furan-2-carboxaldehyde.
1 H NMR (Free base, CDC1 3 9.27 ppm (1 H, br s, NH) 7. 96 (1 H, d, J 8 Hz, NHCHAr); 7.72 (1 H, s, Ar); 7.66 (1 H, di, J 9 Hz, Ar); 7.40 7.23 (5 H, m, Ar); 7.18 7.04 (2 H, in, Ar); 6. 97 (1 H, di, J 8 Hz, Ar) 6. 92 (1 H, di, J 9 Hz, indane C(6)H or 6.76 (1 H, s, benzofuran 6.45 (1 H, di, J 8 H z, CHAr) 3. 76 (2 H, s, CH 2
NH
2 2. 77 2. 60 (4 H, m, indane C(1)H 2 and C(3)H 2 2.10 (3 H, s, CH 3 -Fur); 2.01 1.89 (2 H, m, indane C HA); 1. 64 (2 H, br s, NH 2 UPLO (Luna 2, Gradient rt =4.13 min.
LC/MS (Luna 2, Gradient rt =2.15 min, 440 Example 11 3- (Aminomethyl)benzoyl-D/L-3-methylbenzothiophen-2-ylglycine hydrochloride salt.
From 3-methylbenzothiophene-2-carboxaidehyde.
3 5 IH NMR (Free base, CDC1 3 8. 39 ppm (1 H, br s, NH) 7. 74 WO 01/96305 WO 0196305PCT/GB01/02566 7.62 (4 H, m, NH and Ar); 7.58 (1 H, di, 0 8 HZ, Ar); 7.38 (1 H, di, J 9 Hz, Ar); 7.35 7.23 (4 H, m, Ar); 7.09 (1 H, di, J 10 Hz, indane C(6)H or 6.99 (1 H, J 10 Hz, indane C(6)H or 6.40 (1 H, d, J 8 Hz, CHAr); 3.79 (2 H, S, CH 2
NH
2 2. 75 (2 H, t, J 6 Hz, indane C H 2 orC(3H2 2. 73 (2 H, t, J 6 Hz, indane C H 2 or C H 2 2. 50 (3 H, s,
CH
3 Ar) 2. 00 88 (2 H, m, indane C H 2 1. 55 (2 H, br s,
NH
2 HPLC (Luna 2, Gradient rt =4.33 min.
LC/HS (Luna 2, Gradient rt =2.34 mlin, 470 Example 12 3- (Aminomethyl) benzoyl-D/L-2-phenylthiazol-4-ylglycine indaitrifluoroacetate salt.
Prepared in a similar manner to Example 1 using af--BOC-Di'L-2phenylthiazol-4--ylglycine (synthesised as described below) and Ethyl oximinoacetoacetate.
This was prepared from ethyl acetoacetate (10.00 g) using the method of Fischer (Organic Synthesis Coil. Vol. 3, 513-516) to yield the titled compound (12.45 g).
'B NMR (CDCI,) 1.25 (3 H, 2.35 (3 H, 4.3 (2 H, 8.8 (1 H, br.).
Ethyl chloro-c-oximinoacetoacetate.
This was prepared from ethyl oximinoacetoacetate (1.73 g) using the method of Hatanaka et al. (journal of Medicinal Chemistry, 1973, 16(9), 978-984) to yield the titled compound (1.44 g).
'H NMR (CDCl 3 1.25 (3 H, t) 4. 3 (2 H, q) 4. 55 (2 H, s) 9. (1 H, contains 20% starting material by NMR.
WO 01/96305 PCT/GB01/02566 N-BOC-D/L-2-phenylthiazol-4-ylglycine.
A solution of ethyl y-chloro-a-oximinoacetoacetate (2.10 g, 10.8 mmol) and thiobenzamide (1.49 g, 10.8 mmol) in dry benzene (15 mL) was heated to reflux. After 4 hours, the reaction mixture was poured onto NaHCO 3 (sat., aq., 50 mL); The resulting mixture was extracted with ethyl acetate (2 x mL); and the combined extracts dried over MgSO 4 and evaporated under reduced pressure. Flash chromatography (ethyl acetate:hexane 1:4, Rf 0.30) then afforded impure ethyl aoximino-2-phenylthiazole-4-acetate (3.22 The crude oxime was then dissolved in methanol (15 mL) and formic acid aq., 15 mL) was added. The mixture was cooled to 0 "C and zinc dust (2.00 g, 30.6 mmol) was added portionwise over minutes. The reaction mixture was allowed to warm to room temperature, and stirred for 6 hours. The solution was then filtered, basified to pH 9 with solid NaHC0 3 and extracted with ethyl acetate (3 x 80 mL). The combined extracts were then dried and evaporated to afford D/L-2-phenylthiazol-4ylglycine ethyl ester (1.43 g, 5.45 mmol, 50% from the chlorooxime). The ester (194 mg, 0.74 mmol) was then dissolved in tetrahydrofuran (5 mL). Triethylamine (120 RL, 87 mg, 0.86 mmol) was added, followed by di-t-butyl dicarbonate (180 mg, 0.82 mmol). After stirring at room temperature for 4 days, water (20 mL) was added and the solution extracted with dichloromethane (2 x 20 mL). The combined extracts were evaporated and purified by flash column chromatography (ethyl acetate:hexane 1:4, Rf 0.45) to afford N-t-butyloxycarbonyl- D/L-2-phenylthiazol-4-ylglycine ethyl ester (158 mg, 0.44 mmol, 59%) as a clear oil. The oil was dissolved in tetrahydrofuran (2 mL) and LiOH.H 2 0 (80 mg as a solution in 2 mL water) was added. After stirring at room temperature for 2 hours, water (10 mL) was added, and the solution extracted with ethyl acetate (5 mL). The aqueous layer was then WO 01/96305 WO 0196305PCT/GB01/02566 -67acidified to pH 4 with 2N HC1, and extracted with ethyl acetate (2 x 20 mL); The latter extracts were combined and evaporated to afford N-BOC-D/L-2-phenylthiazol-4-ylglycine (116 mg, 0.35 mmol, 75%) as a white powder.
'H NMR (CDC1 3 10.-81 (1 H, br s, CO 2 H) 7. 80 7. 71 7.30 7.22 (2 H 3 H, m, Ph); 7.21 (1 H, s, thiazole CH); 5.99 (1 H, br d, J 6 Hz, NHBoc) 5. 39 (1 H, br d, J 6 Hz, a-CH); 1. 31 (9 H, s, C (CH 3 3 3- (Aminomethyl)benzoyl-D/L-2-phnylthiazo.-4-ylglyciie indantrifluoroacetate salt.
H NMR (d3 acetonitrile) 9. 00 (1 H, s, NHAr) 8. 15 (1 H, d, J 6 Hz, NHCH); 8.02 (1 H, s, Ar); 7.99 7.88 (2 H, m, Ar); 7.59 7.40 (7 H, m, Ar); 7.25 7.11 (2 x 1 H, 2 x d, 2 x J= 7 Hz, indanyl CHCH); 6.01 (1 H, d, J= 6 Hz); 4.15 (2 H, hr s,
CH
2
NH
2 ;2.9 0 79 (4 H, m, CH 2
CH
2
CH
2 00 (2 pent et, J =6 HZ, CH 2
CH
2
CH
2 HPLC (Luna 2, Gradient rt =4.22 minutes.
LC/MS (Luna 2, Gradient rt =2.29 minutes, 483 WO 01/96305 WO 0196305PCT/GB01/02566 -68- Example 13 3- (Aminomethyl) benzoyl-D/L- (2-methylthiazol-4-yl) glycirie trifluoroacetate salt.
Synthesisedl as described for example 12 using N-BOC-D/L-2methylthiazol-4-ylglycine, which was prepared in an analogous manner to N-BOC-D/L-2-phenylthiazol-4-ylglycine, except that thicacetainide was used in place of thiobenzanide, and aininoindan.
IH NMP. (d 4 MeOR) 8. 00 ppm (2 H, mn, Ar) 7. 8 7. 57 (2 H, m, Ar); 7.48 (2 H, d, J 8 Hz, Ar); 7.30 (1 H, d, J 9 Hz, Ar); 7.16 (1 H, d, J 8 Hz, Ar); 6.01 (1 H, s, CHPh); 4.21 (2 H, s, OH 2
NH
2 2 90 (2 H, t, J =8 Hz, indane C (1)H 2 or C H 2 2.88 (2 H, t, J =8 Hz, indane C (1)H 2 or C H 2 2. 74 (3 H, s, Me); 2.10 (2 H, quintet, J 8 Hz, indane C H 2 HPLC (Luna, Gradient rt =5.92 (92%) LC/MS (Luna 2, Gradient rt 1.88 minutes, 421 Example 14 3- (Aminomethyl)benzoyl-D/L-piperidin-4-ylglycine 4isopropylanilide.
Prepared in a manner analogous to Example 3, except that 4isopropylaniline was used in place of 1'H NMR (d 4 methanol) 8. 04 93 ppm (2 H, in, Ar) 7. 73 7.50 (4 H, mn, Ar); 7.20 (2 H, d, J 7.5 Hz, Ar); 4.67 (1 H, d, J= Hz, OH); 4 .19 (2 H, s CH 2 NH2) 3. 56 3. 41 (2 H, mn, OH 2 pip); 3.12 2. 97 (2 H, in, OH 2 pip); 2. 87 (1 H, quintet, OH ipr); 2.44 2.26 (1 H, mn, Ar); 2.22 1.98 (2 H, mn, OH 2 Pip); 1.87 1.58 (2 H, mn, OH 2 Pip) 1. 28 1.21 (6 H, app. d, 2 x
OH
3 UPLO (Luna 2, Gradient rt =2.18 minutes.
LO/MS (Luna 2, Gradient rt 1.37 minutes, 409 (MH) WO 01/96305 PCT/GB01/02566 -69- Example 3-(Aminomethyl)benzoyl-D/L-piperidin-4-ylglycine 1-acetyl-2,3dihydroindol-6-amide bis(trifluoroacetate) salt.
Prepared in a manner analogous to Example 3 except that 1acetyl-2,3-dihydroindol-6-amine was used in place of aminoindane.
1 H NMR (de DMSO) 8.65 ppm (1 H, br s, NH); 8.34 8.17 (3 H, m, NH); 8.00 (1 H, s, Ar); 7.93 (1 H, d, J 7.5 Hz, Ar); 7.63 (1 H, d, J 7.2 Hz, Ar); 7.55 7.46 (3 H, m, Ar); 7.15 (1 H, d, J= 7.5 Hz, Ar); 4.58 (1 H, d, J 7.5 Hz, CH); 4.14 4.01 (4 H, m, CH 2
NH
2
CH
2 indoline); 3.40 3.27 (2 H, m, CH 2 pip); 3.15 3.02 (2 H, m, CH2 indoline); 2.96 2.73 (2 H, m, CH 2 pip); 2.16 (3 H, s, COCH 3 2.02 1.89 (1 H, m, CH pip); 1.80 1.68 (1 H, m, CH pip); 1.64 1.33 (3 H, m, CH, CH 2 pip).
HPLC (Luna 2, Gradient rt 2.65 minutes.
LC/MS (Luna 2, Gradient rt 0.54 minutes, 450 (MH) Example 16 3-(Aminomethyl)benzoyl-D/L-piperidin-4-glycine 1- (aminoacetyl)-2,3-dihydroindol-6-amide tris(trifluoroacetate) salt.
Prepared in a manner analogous to Example 3 except that 1-(N- BOC-aminoacetyl)-2,3-dihydroindol-6-amine was used in place of 1H NMR (d 4 methanol): 8.46 ppm (1 H, s, Ar); 8.03 7.91 (2 H, m, Ar); 7.70 (1 H, d, J 7.2 Hz, Ar); 7.65 7.54 (1 H, m, Ar); 7.40 (1 H, d, J 7.5 Hz, Ar); 7.21 (1 H, d, J 7.5 Hz, Ar); 4.65 (1 H, d, J 7.5 Hz, CH); 4.21 (2 H, s, CH 2 NH2); 4.16 4.07 (2 H, m, CH 2 indoline); 4.02 (2 H, s, CH 2
NH
2 3.55 3.40 (2 H, m, CH 2 pip); 3.28 3.17 (2 H, m, CH 2 indoline); WO 01/96305 WO 0196305PCT/GB01/02566 3. 10 2. 92 (2 H, iCH 2 p ip) 2. 40 2. 25 (1 HI, m, CH p ip); 2.23 1. 93 (2 H, mCH 2 pip) 1. 86 1. 60 (2 m, CH 2 pip).
HPLC (Luna 2, Gradient rt 2.03 minutes.
LC/MS (Luna 2, Gradient rt =0.64 minutes, 465 Example 17 3- (Aminoinethyl) benzoyl-D/L-1-acetylpiperidin-4-ylglycile trifluoroacetate salt.
3- (N-Z-Aminomethyl) benzoyl-D/L-1-BOC-piperidin-4-ylglycile This compound was prepared in an analogous fashion to 3-(N- BOC-arninomethyl) benzoyl-D/L- (N-BOC-piperidin-4-yl) glycine indan-5-amide, an intermediate in the synthesis of Example 3, except that 3-(N-Z-aminomethyl)benzoic acid was used in the final coupling reaction.
3- (N-Z-Aminomethyl) benzoyl-D/L-1-acetylpiperidin-4-ylglycine A solution of 3- (N-Z-aminomethyl) benzoyl-D/L-1-BOC-piperidin- 4-ylglycine indan-5-amide(65 mng, 0.1 minol) in dichloromethane (3 mL) was stirred at room temperature and trifluoroacetic acid (2 mL, was added. Stirring was continued for an hour and the solvents were removed under reduced pressure.
The residue was taken up in dichioromethane (5 mL) and treated with triethylamine (0.055 mL, 0.4 inmol) and acetyl chloride (0.014 inL, 0.2 inmol) and allowed to stir for 1 hour. The solution was washed with water (3 x 5 mL) dried (MgSO 4 and concentrated under reduced pressure. The residue was purified by flash chromatography using methanol dichioromethane (1:9) as eluent to afford a colourless solid (45 mng, 78 'H NMR (d 4 methanol) 7.02 7. 68 ppm (2 H, m, Ar) 7.51 7. WO 01/96305 PCT/GB01/02566 -71- (9 H, m, Ar); 7.16 (1 H, d, J 7.2 Hz, Ar); 5.09 (2 H, s,
OCH
2 Ph); 4.65 4.47 (2 H, m, CH and NH); 4.31 (2 H, s,
CH
2
NH
2 4.00 3.85 (1 H, m, CH pip); 3.14 2.97 (1 H, m, CH pip); 2.92 2.77 (4 H, m, 2 x CH 2 indane); 2.66 2.48 (1 H, m, CH pip); 2.32 2.17 (1 H, m, CH pip); 2.15 1.90 (6 H, m, COCH3, CH 2 ind, CH pip); 1.85 -1.67 (1 H, m, CH pip); 1.53 1.20 (2 H, m, CH 2 pip).
3-(Aminomethyl)benzoyl-D/L-1-acetylpiperidin-4-ylglycine indan-5-amide trifluoroacetate salt.
Palladium on carbon (20 mg) was added to a solution of 3- (N-Carbobenzyloxy-amninomethyl)benzoyl-D/L-l-acetylpiperidin-4ylglycine indan-5-amide (45 mg, 0.08 mmol) in methanol (20 mL) and the suspension was stirred under a hydrogen atmosphere overnight. The mixture was filtered and the filter was washed with methanol (20 mL). The combined filtrates were concentrated under reduced pressure and the amine was purified by flash chromatography using methanol dichloromethane (1:9) as eluant to afford a colourless solid. Trifluoroacetic acid (1 mL) was added and the solution was concentrated under reduced pressure to give the TFA salt (16 mg, 36 1H NMR (d 4 methanol): 7.98 7.87 ppm (2 H, m, Ar); 7.73 7.20 (4 H, m, Ar); 7.10 (1 H, d, J 7.2 Hz, Ar); 4.55 (1 H, s, CH); 4.15 (2 H, s, CH 2
NH
2 4.00 3.82 (2 H, m, CH 2 pip); 3.15 2.95 (1 H, m, CH pip); 2.89 2.71 (4 H, m, 2 x CH 2 indane); 2.66 2.48 (1 H, m, CH pip); 2.29 2.11 (1 H, m, CH pip); 2.10 1.85 (6 H, m, COCH 3
CH
2 ind, CH pip); 1.81 1.62 (1 H, m, CH pip); 1.50 1.19 (2 H, m, CH 2 pip).
HPLC (Luna 2, Gradient rt 3.64 minutes.
LC/MS (Luna2, Gradient rt 1.75 minutes, 449 (MH) Examples 18 20 were prepared in a manner analogous to Example 17, except that the indicated carboxylic acid WO 01/96305 WO 0196305PCT/GB01/02566 -72derivative was used to form the arnide of the piperidine nitrogen, under appropriate conditions.
Example 18 3- (Aiinomethyl) benzoyl-D/L- (1-propanoyl) piperidin-4-ylglycine trifluoroacetate salt.
From propanoyl chloride.
1H NMR (d 4 methanol1): 7. 80 ppm (2 H, s, Ar); 7. 59 7. 41 (2 H, m, Ar); 7.36 (1 H, s, Ar); 7.16 (1 H, d, J= 7.2 Hz, Ar); 7.03 (I H, d, J 7.2 Hz, Ar); 4.53 4.39 (2 H, m, CH, CH pip); 4. 04 (2 H, s CH 2
NH
2 3. 07 2. 90 (1 H, m, OH p ip) 2. 86 2. 70 (4 H, m, 2 x CH 2 irid) 2. 61 2. 43 (1 H, mn, CH pip) 2. 36 2.22 (2 H, m, COCH 2
CH
3 2.19 2. 04 (1 H, m, OH pip) 2. 01 1. 79 (3 H, m, OH 2 ind, CH pip); 1. 76 1. 60 (1 H, m, OH pip); 1. 41 1. 10 (2H, m, OH 2 Pip) 0. 93 (3 H, t, J 5 Hz,
COCH
2
OH
3 HPLC (Luna 2, Gradient rt 3.54 minutes.
LC/MS (Luna 2, Gradient 4):rt =1.96 minutes, 463 Example 19 3- (Aminomethyl) benzoyl-D/L- (1-isobutyryl)piperidin--4-ylglycine From isobutyryl ohloride.
1'H NMR (d 4 methanol): 7.75 ppm (I H, s, Ar); 7.67 (1 H, d, J= 7.2 Hz, Ar); 7.42 (1 H, d, J 7.2 Hz, Ar); 7.38 7.29 (2 H, m, Ar) 7. 18 (1 H, cd, J7= 7. 5 H z, Ar) 7 03 (1 H, d, J 7. Hz, Ar); 4.57 4.41 (1 H, m, OH); 4.09 3.95 (1 H, m, OH pip) 3. 81 (2 H, S, OH 2
NH
2 3. 10 2. 94 (1 H, m, OH pip) 2. 91 2. 67 (5 H, m, CH ipr, 2 x OH 2 ind) 2. 62 2. 43 (1 H, m, CH pip); 2.25 2.07 (1 H, mn, OH pip); 2.04 1.59 (4 H, m, OH 2 3 5 ind, 2 x OH pip) 1. 43 12 (2 H, m, OH 2 Pip) 0.-9 8 (6 H, m, 2 WO 01/96305 WO 0196305PCT/GB01/02566 -73x CH 3 HPLC (Luna 2, Gradient rt =3.39 minutes.
LC/MS (Luna 2, Gradient rt =1.88 minutes, 477 (MH) t S Example 3- (Amiriomethyl) benzoyl-D/L- (1-aminoacetyl) piperidin-4ylglycine iridan-5-azuide bis(trifluoroacetate) salt.
From N-BOC-glycine.
IH NMR (d 4 methanol) 7. 94 7. 81 ppm (2 H, m, Ar) 7. 58 (1 19, d, J 7.2 Hz, Ar); 7.54 7.44 (1 11, m, Ar); 7.38 (1 H, s, Ar); 7. 20 (1 H, d, LT= 7. 5 Hz, 7. 08 (1 H, d, J 7. 2 Hz, Ar); 4.54 -4.40 (1 H, m, CR); 4.10 (2 H, s, CH 2
NH
2 3.95- 3.76 (2 H, m, COCH 2
NH
2 3.734 3. 65 (1 H, m, CR pip); 3. 12- 2.96 (1 H, m, CH pip); 2.84 2.58 (5 H, m, 2 x CR 2 ind, CH pip) 2. 26 2. 07 (1 H, mn, CH pip) 2. 04 1. 84 (3 H, m, CH 2 mnd, CH pip); 1.79 1.69 (1 H, m, CH pip); 1.53 1.04 (2 H, m, eli 2 Pip) HPLC (Luna 2, Gradient rt =2.65 minutes.
LC/MS (Luna 2, Gradient rt =1.35 minutes, 464 Example 21 3- (Aminomethyl)benzoyl-D/L-indan-5-ylglycine trifluoroacetate salt.
acid A solution of 5-acetylindane (2.0 g, 12.5 mmol) in 1,4-dioxane (20 mL) was stirred at room temperature. Sodium hydroxide g, 125 mmol) in water (20 mL) was then added, followed by enough of a solution of potassium hydroxide and iodine in water (20 g KOH, 10 g 12, 50 mL H 2 0) to give a permanent iodine colour 10 mL) The mixture was heated at 60 0 C for 1. 5 hours when further 12 and KOH solution (5 mL) was added and heating WO 01/96305 PCT/GB01/02566 -74was continued for a further 16 hours. The solution was cooled, poured into water (150 mL) and extracted with diethyl ether (3 x 25 mL). The aqueous solution was then made acidic with 6 N HC1, causing a brown oil to separate. This was extracted into ethyl acetate (3 x 50 mL), which was dried (MgSO 4 and evaporated to afford the crude acid as a brown solid (1.41 g, 70 Methyl A solution of the crude acid (1.41 g, 8.7 mmol) in methanol mL) was cooled under Ar to 0°C. Thionyl chloride (0.76 mL, 1.24 g, 10.4 mmol) was added by syringe and the solution was stirred for 48 hours, warming slowly to room temperature. The methanol was evaporated, the residue was partitioned between ethyl acetate (100 mL) and water (50 mL) and NaHCO 3 was added until gas evolution ceased. The layers were separated, the aqueous phase was extracted with ethyl acetate (2 x 30 mL) and the combined organics were washed with water (30 mL), saturated NH 4 C1 30 mL), water (30 mL) and brine (30 mL) and dried over MgSO 4 Evaporation of the solvent afforded a dark brown oil, which was purified by flash column chromatography (silica gel, 10 EtOAc/Hexane eluent) to afford the ester as a pale yellow low-melting solid (490 mg, 32 A solution of the ester (480 mg, 2.7 mmol) in THF (30 mL) was cooled under Ar to 0°C and DIBAL-H (1M in toluene, 6.8 mL, 6.8 mmol) was added by syringe. The solution was stirred overnight, warming to room temperature. No starting material was indicated by tlc, so the solution was cooled back to 0 C and quenched by adding Na 2
SO
4 .10 H 2 0 2 g) and stirring vigorously for two hours. The mixture was diluted with ethyl WO 01/96305 PCT/GB01/02566 acetate (25 mL) and filtered, rinsing the solid well with ethyl acetate. Evaporation of the solvent afforded the alcohol as a pale yellow solid (375 mg, 93 A solution of the alcohol (370 mg, 2.5 mmol) in dichloromethane (10 mL) was stirred at room temperature. N- Methylmorpholine-N-oxide (307 mg, 2.62 mmol) and powdered 4A molecular sieves 1 g) were added and the mixture was stirred under Ar for 30 minutes. Tetrapropylammonium perruthenate (44 mg, 0.12 mmol) was added in one portion and stirring was continued for 30 minutes. Tic indicated some starting material remaining, so further N-methylmorpholine-Noxide (100 mg, 0.85 mmol) was added and stirring continued for an additional 30 minutes. The mixture was evaporated onto SiO 2 g) and purified by flash column chromatography (SiO 2 EtOH/Hexane eluent) to afford the aldehyde as a pale yellow oil (299 mg, 82 3-(BOC-Aminomethyl)benzoyl-D/L-N-(2,4-dimethoxybenzyl)indan-5ylglycine The aldehyde (208 mg, 1.4 mmol) and 2,4-dimethoxybenzylamine (215 OL, 238 mg, 1.4 mmol) were mixed in dichloromethane (2 mL) and allowed to stand for an hour. The solution was diluted up to 5 mL, dried over Na 2
SO
4 and added to 3-(BOCaminomethyl)benzoic acid (360 mg, 1.4 mmol). A solution of (0.29 M in CH 2 C12, 5 mL, 1.4 mmol) was then added and the mixture allowed to stir for 26 days at room temperature. The solvent was evaporated onto SiO 2 g) and purified by Biotage Flash 40 chromatography, eluting with hexane/ethyl acetate (2:1 to 1:1) to afford the protected amide as a pale yellow foamy solid (385 mg, 40 WO 01/96305 PCT/GB01/02566 trifluoroacetate salt.
A solution of the protected amide (385 mg, 0.55 mmol) and triethylsilane (180 pL, 130 mg, 1.1 mmol) in dichloromethane mL) was stirred at room temperature and trifluoroacetic acid mL) was added. After 1.5 hours the dichloromethane and excess trifluoroacetic acid were evaporated and the residue was purified by SCX ion exchange chromatography, eluting with 5 2 N NHs/MeOH in DCM, to afford the free amine as a pale yellow glassy solid. This was taken up in methanol (30 mL) and trifluoroacetic acid (5 drops) was added. The methanol and excess trifluoroacetic acid were evaporated and the residue taken up in water and lyophyllised to afford the amine trifluoroacetate salt as an off-white powder (178 mg, 58 1H NMR (d 6 DMSO): 10.15 ppm (1 H, s, NH); 8.70 (1 H, d, J 9 Hz, NH); 8.09 (3 H, br s, NH3) 7.95 (1 H, s, Ar); 7.88 (1 H, d, J 10 Hz, Ar); 7.53 (1 H, d, J 9 Hz, Ar); 7.50 7.38 (2 H, m, Ar); 7.31 (1 H, s, Ar); 7.24 7.17 (2 H, m, Ar); 7.11 (1 H, d, J 9 Hz); 7.03 (1 H, d, J 9 Hz, Ar); 5.68 (1 H, d, J 8 Hz, CHPh); 4.00 (2 H, br s, CH 2
NH
3 2.82 2.58 (8 H, m, 2 x indane C(1)H 2 and C(3)H 2 1.98 1.80 (4 H, m, 2 x indane C(2)H 2 HPLC (Luna 2, Gradient rt 2.83 min.
LCMS (Luna 2, Gradient rt 2.37 min, 440 Example 22 3-(Aminomethyl)benzoyl-D/L-6-amino-3-pyridylglycine amide bis(hydrochloride) salt.
Prepared in a similar manner to Example 21, using 6-(N-BOCamino)pyridine-3-carboxaldehyde, synthesised as described below.
WO 01/96305 PCT/GB01/02566 -77- Methyl 6-aminonicotinate A suspension of 6-aminonicotinic acid (2.0 g, 14.5 mmol) and sulfuric acid (2 mL) in methanol (125 mL) was heated at reflux overnight. The solution was cooled, the methanol evaporated and the residue was taken up in water (100 mL) and made basic with NaHCO 3 causing a white solid to precipitate. The mixture was extracted with chloroform (3 x 40 mL) and the combined extracts were dried (MgS04) and evaporated to afford the ester as an off-white solid (1.04 g, 30 Methyl 6-(N-BOC-amino)nicotinate A solution of the amine (1.0 g, 6.6 mmol) in dichloromethane mL) was stirred at room temperature and 4-N,Ndimethylaminopyridine (40 mg, 0.33 mmol), di-t-butyldicarbonate (1.51 g, 6.9 mmol) and triethylamine (970 DL, 700 mg, 6.9 mmol) were added. The solution was stirred for two hours before the dichlormethane was evaporated and the oily residue was purified by flash column chromatography (SiOz, 20 ethyl acetate/hexane eluent) to afford the protected amine as a white crystalline solid (1.6 g, quantitative).
6-(N-BOC-Amino)-3-(hydroxymethyl)pyridine A solution of the ester (1.36 g, 5.4 mmol) in dry THF (90 mL) was cooled to 0°C under Ar. DIBAL-H (1 M in toluene, 11.3 mL, 11.3 mmol) was added by syringe and the solution was stirred for 1.5 hours. Tic indicated that starting material was still present, so further DIBAL-H solution (6 mL) was added, and again after an additional two hours. After a further hour the reaction was quenched by the addition of Na 2
SO
4 .10 H20 -3 g) at 0°C, and stirred vigorously. The mixture was diluted with diethyl ether (80 mL) and filtered, rinsing well with WO 01/96305 WO 0196305PCT/GB01/02566 -78diethyl ether. Evaporation of the solvents afforded the alcohol as a white solid (1.20 g, 98 6- (N-BOC-Amino) pyridine-3-carboxaldehyde
S
A solution of the alcohol (780 mg, 3.5 mmcl) in dichioromethane (40 mL) was stirred at room temperature and powdered 4A molecular sieves g) and N-methylmorpholine-Noxide (510 mg, 4.35 mmiol) were added. After thirty minutes tetrapropylammonium perruthenate (61 mg, 0.17 mxnol) was added and stirring continued at room temperature. Further Niethylmorpholine-NT-oxide (500 mg) and tetrapropylarmonium perruthenate (50 mg) had to be added before the reaction went to completion, after stirring overnight. The mixture was filtered through a short silica pad, eluting with 2:1 hexane/'etinvi acetate. Evaporation of the solvents afforded the aldehyde as an off-white solid (524 mg, 68 3- (.minomethy1) benzoyl-D/L-6-amino-3-pyridylglycine amide bis(hydrochloride) salt I H NMR (D 2 0) 7. 97 7. 84 ppm (2 H, m, Ar) 7. 75 (2 H, s, Ar); 7.57 (1 H, d, J 8 Hz, Ar); 7.53 7.42 (1 H, m, Ar); 7.28- 7.12 (2 H, in, Ar) 7. 06 (1 H, d, J= 10 Hz, Ar) 6.95 (1 H, d, J 11 Hz, Ar) 5.56 (1 H, s, CHPy); 4.09 (2 H, CH 2
NH
2 2.80- 2. 68 (4 H, mn, indane C (1)H 2 and C H 2 1.-90 (2 H, pentet, J= 8 H z, indane C H 2
I'
HPLC (Luna 2, Gradient rt 3.27 rmin.
LONS (Luna 2, Gradient rt 1.63 min, 416 Example 23 3- (Aminomethyl) benzoyl-D/L-2-chloro-3-pyridylglycize amide bis(hydrochloride) salt.
WO 01/96305 PCT/GB01/02566 -79- Prepared in a similar manner to Example 21, using 2chloropyridine-3-carboxaldehyde, synthesised as described below.
Methyl 2-chloronicotinate A solution of 2-chloronicotinic acid (1.61 g, 10.2 mmol) and sulfuric acid (0.5 mL) in methanol (30 mL) was stirred at reflux overnight. The solution was poured into water (100 mL) and neutralised with NaHC0 3 before being extracted with 1:1 hexane/ethyl acetate (3 x 40 mL). The solvents were dried (MgSO 4 and evaporated and the residue was purified by flash column chromatography (SiO 2 25 ethyl acetate/hexane eluent) to afford the ester as a colourless oil (700 mg, 40 2-Chloro-3-(hydroxymethyl)pyridine A solution of the ester (460 mg, 2.45 mmol) in dry THF (25 mL) was stirred at 0°C under Ar. A solution of DIBAL-H in toluene (lM, 5.2 mL, 5.2 mmol) was added by syringe, the solution was stirred for 1.5 hours and then further DIBAL-H (1.2 mL) was added and stirring continued overnight allowing the temperature to rise to ambient. The solution was then cooled back to 0°C and quenched by adding Na2SO4.10 H20 2 g) and stirring vigorously for 30 minutes. The mixture was diluted with ethyl acetate (20 mL) and filtered, rinsing the solid well with further ethyl acetate. Evaporation of the solvents afforded the alcohol as a viscous pale yellow oil (360 mg, quant.) which was used without further purification.
2-Chloropyridine-3-carboxaldehyde A solution of the alcohol (350 mg, 2.45 mmol) in dichloromethane (20 mL) was stirred at room temperature and and powdered 4A molecular sieves g) and N- WO 01/96305 WO 0196305PCT/GB01/02566 methylinorpholine-N7-oxide (500 mg, 3.68 mmol) were added.
After thirty minutes tetrapropylammonium perruthenate (43 mg, 0.12 mmcl) was added and stirring continued at room temperature for one hour. The mixture was filtered through a short silica pad, eluting with 1:1 hexane/ethyl acetate.
Evaporation of the solvents afforded the aldehyde as a pale yellow solid (236 mng, 68 3- (.minomethyl)benzoyl-D/L-2-chloro-3-pyridylglycine am~ide bis(hydrochloride) salt 'H NMR (D 2 8. 18 ppm (1 H, d, J 3 Hz, Pyridine C H) 7. 82 (I H, d, JT 10 Hz, Ar) 7. 66 (2 H, s, Ar); 7. 49 (1 H, d, J= Hz, Ar); 7.45 7.36 (1 H, in, Ar); 7.35 -7.28 (1 H, mn, Pyridine 7.18 7.05 (2 H, m, Ar); 6.96 (1 H, d, J 9 Hz, Ar) 5.95 (1 H, s, CHPh) 4.06 (2 H, s, CH 2 NHq 2 2. 65 (4 H, br s, indane C H 2 and C (3)HI 2 1. 78 (2 H, pentet, J 8 Hz, indane C H 2 HPLC (Luna 2, Gradient rt =3.84 mini.
LCMS (Luna 2, Gradient rt =1.97 min, 435 Example 24 3- (.Amnomethy)benzoyl-D/L-indol-5-ylglycine trifluoroacetate salt.
Prepared from N-BOC-indole-5-carboxaldehyde in a similar manner to example 21. The aldehyde was synthesised from methyl indole-5-oarboxylate by appropriate protection and functional group manipulation as described for example 22.
'H NMR (CDCl 3 free base) 8. 32 ppm (1 H, d, J 8 H z, NH); 7.88 7.62 (4 H, m, Ar and NH); 7.47 7.26 (5 H, m, Ar and NH); 7.15 (1 H, s, Ar); 7.13 6.99 (2 H, in, Ar); 6.44 (1 H, s, Ar) 5. 91 (1 H, t, J 6 Hz, indole C H) 4. 38 (1 H, s, WO 01/96305 WO 0196305PCT/GB01/02566 -81- CHAr) 3. 80 (2 H, s, CH 2
NH
2 2. 76 (4 H, t, J 7 Hz, indane C (1)H 2 and C H 2 2. 00 1.'88 (2 H, m, indane C H 2 1. 65 (2 H, br s, NH 2 HPLC (Luna 2, Gradient rt 4.09 min.
LCMS (Luna 2, Gradient rt 2.12 min, 439 Example 3- (Aminomethyl) benzoyl-D/L-2, indan-5-amide hydrochloride salt.
Prepared using method 2 from commercially available 2,3- 1 H NNR (CDC1 3 free base): 9.14 ppm (1 H, s, NH); 7.91 (1 H, d, J 8 Hz, NH); 7.84 (1 H, s, Ar); 7.80 (1 H, d, J 8 Hz, Ar); 7.52 )1l H, d, J 7 Hz, Ar); 7.48 7.31 (3 H, in, Ar); 7.23 (1 H, d, J 9 Hz, Ar) 7.08 (1 H, d, J 9 Hz, Ar) 6.72 (1 H, d, J 9 Hz, Ar); 6.20 (1 H, d, JT= 8 Hz, CHAr); 4.54 (2 H, t, JT= I Hz, dihyclrobenzof uran C H 2 3. 92 (2 H, s,
CH
2
NH
2 3. 16 2. 98 (2 H, m, dihydrobenzof uran C H 2 2. 92 2.80 (4 H, m, indane C H 2 and C H 2 2.07 (2 H, pentet, J 8 Hz, indane C H 2 1. 66 (2 H, br s, NH 2 HPLC (Luna 2, Gradient rt 4.13 muin.
LCMS (Luna 2, Gradient rt 2.00 min, 442 Example 26 3- (Aminomethyl) benzoyl-D/L--2-benzylthiazol-4-ylglycine indan- 5-amide trifluoroacetate salt Synthesised as described for example 12 using N-BOC-D/L-2benzylthiazol-4-ylglycine (which was prepared in an analogous manner to N-BOC-D/L-2-phenylthiazol-4-ylglycine, except that thiobenzylamide was used in place of thicbenzamide) and WO 01/96305 WO 0196305PCT/GB01/02566 -82amino indane.
'H NMR (d 3 acetonitrile) 9. 17 (1 H, br s, NH) 8. 26 (1 H, d, J =8 Hz, Ar); 8.08 (1 H, s, Ar); 7.91 (1 H, di, J 8 Hz, Ar); 7.62 (1 H, di, J 8 Hz, Ar); 7.52 (1 H, t, J 8 Hz, Ar); 7.43 (1 H, s, Ar); 7.4 7.26 (5 H, mn, Ar); 7.23 (1 H, d, J 8 Hz, Ar); 7.15 (1 H, d, J 8 Hz, Ar); 5.94 (1 H, d, J 7 Hz, CHthiazole), 4.32 (2 H, s, CH 2 Ph) 4. 19 (2 H, s, CH 2
NH
2 2. 87 (4 H, in, CH 2
CH
2
CH
2 2. 07 (2 H, pentet, J 5 Hz, CH 2
CH
2
CH
2 Hplc (Luna 2, Gradient rt =4.67 minutes.
LC/MS (Luna 2, Gradient rt =2.40 minutes, 497 Example 27 3- (Aminomethyl) benzoyl-D/L-2-ethylthiazol-4-ylglycine amide trifluoroacetate salt Synthesised as described for example 12 using N-BOC-D/L-2ethylthiazol-4-ylglycine (which was prepared as described below) and N-t-butyloxycarbonyl-DL-2 -ethylthiazol-4-ylglycine A solution of ethyl y-chloro-a-oximinoacetoacetate 00 g, 10.3 mmol) and thiopropionamide (0.92 g, 10.3 inmol) in dry benzene (15 rnL) was heated to reflux. After 4 hours, the reaction mixture was poured onto NaHCO 3 (sat. ag. 50 mL) The resulting mixture was extracted with ethyl acetate (2 x mL) and the combined extracts dried over MgSO 4 and evaporated under reduced pressure. Flash chromatography (ethyl acetate:hexane 1:4) then afforded impure ethyl oc-oxixnino-2ethylthiazole-4-acetate (0.83g) The crude oxime was then dissolved in methanol (25 mL) and formic acid (50% aq., 10 mL) was added. The mixture was cooled to 0 0 C and zinc dust 00 g, WO 01/96305 PCT/GB01/02566 -83- 15.3 mmol) was added portionwise over 30 mins. The reaction mixture was allowed to warm to room temperature, and stirred for 6 hours. The solution was then filtered, basified to pH 9 with solid NaHCO 3 and extracted with ethyl acetate (3 x mL). The combined extracts were then dried and evaporated to afford DL-2-ethylthiazol-4-ylglycine ethyl ester (0.56 g, 2.6 mmol). The ester (560 mg, 2.6 mmol) was then dissolved in tetrahydrofuran (50 mL). Triethylamine (0.4 mL, 3.9 mmol) was added, followed by di-t-butyl dicarbonate (0.57 g, 2.6 mmol).
After stirring at room temperature overnight the mixture was concentrated, water (20 mL) was added and the solution extracted with ethyl acetate (2 x 20 mL). The combined extracts were evaporated to afford N-t-butyloxycarbonyl-D/L-2ethylthiazol-4-ylglycine ethyl ester (824 mg,) as a golden oil. The oil was dissolved in methanol (25 mL) and aqueous sodium hydroxide (2 M, 5 mL) was added. After stirring at room temperature for 2 hours, the solution was concentrated, water mL) was added, and the solution extracted with ethyl acetate (30 mL). The aqueous layer was then acidified to pH 4 with 2 N HC1, and extracted with ethyl acetate (2 x 20 mL), The latter extracts were combined and evaporated to afford Nt-butyloxycarbonyl-D/L-2-ethylthiazol-4-ylglycine (450 mg) as a white solid.
1H NMR (CDC1 3 10.1 (1 H, br s, CO 2 7.20 (1 H, s, thiazole CH), 5.85 (1 H, br d, J 6 Hz, NHBoc), 5.52 (1 H, br d, J 6 Hz, a-CH), 3.05 (2 H, q, J= 5 Hz, CH 2
CH
3 1.49 (9 H, s,
C(CH
3 3 1.42 (3 H, t, J= 5 Hz, CH 2
CH
3 3-(Aminomethyl)benzoyl-D/L-2-ethylthiazol-4-ylglycine amide trifluoroacetate salt IH NMR (d 4 MeOH): 8.0 (2 H, d, Ar); 7.68 (1 H, d, J= 8 Hz, Ar); 7.60 (1 H, t, J 8 Hz, Ar); 7.50 (2 H, s, Ar); 7.30 (1 H, d, J 8 Hz, Ar); 7.15 (1 H, d, J 8 Hz, Ar); 6.00 (1 H, WO 01/96305 WO 0196305PCT/GB01/02566 -84s, CR-thiazole) 4. 2 (2 H, s, CH 2
NH
2 3. 07 (2 H, q, J 6 Hz,
CH
2 CH3) 2. 88 (4 H, m, CH 2
CH
2
CH
2 2. 09 (2 H, pentet, J 6 Hz,
CH
2
CH
2
CH
2 1. 40 (3 H, t, J 6 Hz, CH2CH 3 Hplc (Luna 2, Gradient rt 4.15 minutes.
IJC/MS (Luna 2, Gradient rt =2.07 minutes, 435 Example 28 3- (Aminomethyl) benzoyl-D/L-2 -methylthiazol-4-ylglycine 1acetyl-2 ,3-dihydroindo1-6-amide trifluoroacetate salt.
Synthesised as described for example 12 using N-BOC-D/L-2methylthiazol-4-ylglycine (which was prepared in an analogous manner to N\-BOC-D/L-2-phenylthiazol-4-ylglycine, except that 1S thioacetamide was used in place of thiobenzamide) and Nacetyi-6-aminoindoline.
I H NMR (d 4 MeOH) 8.3 (1 H, m. Ar) 8.01 (2 H, m, Ar) 7. 60 (1 H, d, J 9 Hz, Ar) 7. 62 (1 H, t, JT= 9 Hz, Ar) 7. 51 (1 H, s, Ar) 7.45 (1 H, d, J 9 Hz, Ar) 7.19 (1 H, d, J= 9 Hz, Ar) 6. 00 (1 H, s, CH-thiazole) 4. 21 (2 H, s, CH 2
NH
2 4. 17 (2 H, t r J 6 Hz CH 2 indoline) 3. 18 (2 H, t, J 6 Hz
CH
2 indoline) 2. 73 (3 H, s, thiazole-CH 3 2. 25 (3 H, s,
COCH
3 Hplc (Luna 2, Gradient rt =3.14 minutes.
LC/MS (Luna 2, Gradient rt =1.67 minutes, 464 Example 29 3- (Aminomethyl) benzoyl-D/L-2-methylthiazol-4-ylglycine 2,3dihydroindol-6-amide bis (trifluoroacetate) salt.
Synthesised as described for example 12 using N-BOC-D/L-2methylthiazol-4-ylglycine (which was prepared in an analogous manner to N-BOC-D/L-2-phenylthiazol-4-ylglycine, except that WO 01/96305 WO 0196305PCT/GB01/02566 thioacetamide was used in place of thiobenzanide) and 6aminoindoline using suitable protecting group strategy.
'H NMR (d 4 MeOH) 7. 9 (2 H, br s, Ar) 7. 78 (1 H, s, Ar) 7.5 8 (1 H, d, J 8 Hz, Ar); 7.52 (1 H, t, J 8 Hz, Ar); 7.38 (1 H, s, Ar); 7.26 (2 H, s, Ar); 5.88 (1 H, s, CH-thiazole); 4.11 (2 H, s, CH 2
NH
2 3. 69 (2 H, t, J 7 Hz CR 2 indoline) 3.15 (2 H, t, J 7 Hz, CH 2 indoline) 2. 62 (3 H, s, thiazole-
CR
3 Hplc (Luna 2, Gradient rt =2.358 minutes.
LC/MS (Luna 2, Gradient rt =1.19 minutes, 422 Example 3- (Aminomethyl)benzoyl-D/L-2- (dimethylaininoacetylamino) thiazol-4-ylglycine bis (trifluoroacetate) salt.
3- (N-BOC-aminomethyl) benzoyl-D/L-2-aminothiazol-4-ylglycine indanamide To a stirred solution of NT-Boc-D/L-(2-Z-amino-4thiazoyl)gl-ycine (the amine was prepared by the method of Hardy, Harrington, F. and Stachuiski, J. Chemn. Soc.
Perkin Trans 1 (1984) 1227-1235 and then protected using standard conditions) (l.0 g, 2.45 rnxol), 1-[3- (dimethylamino) propyll -3-ethylcarbodiimide hydrochloride (565 mig, 2.95 mmol), l-hydroxy--7-azabenzotriazole (401 mg, 2.95 mmol) and DMAP (cat) in dimnethylformamide (10 mL) was added a solution of 5-aminoindane (393 mg, 2.65 rnmol) in dimethylformamide (10 mL) and the mixture was stirred overnight. The dimnethylforrnamide was evaporated under reduced pressure, and the resulting oil partitioned between water mL) and ethyl acetate (50 mL) The ethyl acetate layer was washed with 5% hydrochloric acid (10 mL), saturated sodium WO 01/96305 PCT/GB01/02566 bicarbonate solution (10 mL), dried (MgSO 4 and evaporated under reduced pressure to give a brown foam (1.0 g).
The foam was dissolved up in acetic acid (27 mL), and to this stirred solution was added 30% HBr/acetic acid(13.5 mL), then heated at 60 0 C for 4 hours. The solvent was then evaporated and the residue partitioned between ethyl acetate (30 mL) and NaHCO 3 (sat. aq., 20 mL). The ethyl acetate layer was then washed with water (20 mL) and brine (20 mL). The dried (MgSO 4 ethyl acetate layer was evaporated in vacuo to give a brown gum (490 mg).
The brown gum was dissolved in dichloromethane (20 mL) and treated with trifluoroacetic acid (5 mL) for 2 hours. The mixture was then evaporated in vacuo to give an oil.
The oil, dissolved in dimethylformamide (10 mL), was then added to a stirred solution of 3-(N-BOC-aminomethyl)benzoic acid (480 mg, 1.91 mmol), l-[3-(dimethylamino)propyl]-3ethylcarbodiimide hydrochloride (441 mg, 2.3 mmol), 1-hydroxy- 7-azabenzotriazole (313 mg, 2.3 mmol) and triethylamine (0.70 mL, 5 mmol) in dimethylformamide (15 mL) and the solution allowed to stir for 2.5 hours. The dimethylformamide was evaporated under reduced pressure, and the resulting oil partitioned between water (50 mL) and ethyl acetate (50 mL).
The ethyl acetate layer was washed with 5% hydrochloric acid mL), and NaHCO 3 (sat. aq., 10 mL), dried (MgSO 4 and evaporated under reduced pressure. The residue was absorbed onto silica and purified by column chromatography, eluting with 30 50% ethyl acetate hexane. The desired fractions were combined and evaporated to give the amine as a light brown foam (270 mg).
H NMR (d6 DMSO): 10.2 (1 H, s, NH-indane); 8.62 (1 H, d, J 8 Hz, NHCH-thiazole); 7.77 (2 H, m, Ar); 7.55 (1 H, s, Ar); 7.43 (2 H, t, J 6 Hz, NHBoc); 7.40 (1 H, d, J 9 Hz, Ar); 7.30 (1 H, d, J 9 Hz, Ar); 7.13 (1 H, d, J 9 Hz, Ar); 7.03 (2 H, s, NH 2 6.48 (1 H, s, Ar); 5.67 (1 H, s, CH-thiazole); 4.18 WO 01/96305 WO 0196305PCT/GB01/02566 -87- (2 H, d, J 6 Hz, CH 2
NH
2 2. 80 (4 H, m, J 7 Hz, CH 2
CH
2
CH
2 2. 00 (2 H, pentet, J 7 Hz, CH 2
CH
2
CH
2 1. 38 (9 H, s. C (CH 3 3 3- (Aminomethyl) benzoyl-D/L-2- (diinethylaiuinoacetylainino) thiazol-4-ylglycine A solution of the amine (154 mng, 0.30 inmol) in dimethylformamide (10 mL) was added to a stirred solution of N,N-dimethylglycine (56 mng, 0.54 rnmol), 1-[3- (dimethylamino) propylj -3-ethylcarbodlimide hydrochloride (86 mg, 0.45 mmol), l-hydroxy-7-azabenzotriazole (80 mg, 0.59 mmcl) and DMAP (oat) in dimethylformamide (15 mL) and allowed to stir for 24 hours. Further 1-[3-(dlmethylamino)propyl]-3ethylcarbodilmide hydrochloride (29 mng, 0.15 irmol) and 1hydroxy-7-azabenzotriazole (20 mng, 0.15 minol) were added and the solution was heated at 50'C for 6 days. The mixture was cooled, tho solvent evaporated under reduced pressure, and the residue dissolved in dichloromethane (10 ml) The stirred solution was then treated with trifluoroacetic acid (1 mL).
After 2 hours the dichloromethane and excess trifluoroacetic acid were evaplorated under reduced pressure and the residue purified by preparative hplc to afford the title compound as a white solid.
1H NNR (d 4 MeOE-) 8. 02 (2 H, d, J 8 Hz, Ar) 7. 72 7. 58 (2 H, m, Ar); 7.50 (1 H, s, Ar); 7.32 (2 H, mn, Ar); 7.17 (1 H, d, J 8 Hz, Ar); 6.01 (1 H, s, CH-thiazole); 4.28 (2 H, s,
CH
2 NMe 2 4 .21 (2 H, s, CH 2
NH
2 3. 04 (6 H, s, CH 2 NMe 2 2. 90 (4 H, M. CH 2
CH
2
CH
2 2. 10 (2 H, pentet, J 6 Hz, CH 2
CH
2
CH
2 Hplc (Luna 2, Gradient rt =3.40 minutes.
LC/MS (Luna 2, Gradient rt =1.47 minutes, 507 Examples 31 and 32 were synthesised in the same way as example WO 01/96305 WO 0196305PCT/GB01/02566 -88but using the indicated reagent in place of N,Ndimethyiglycine.
Example 31 3- (Aiinomethyl) benzoyl-D/L-2- (hydroxyacetylamino) thiazol-4ylglycine Prepared using acetoxyacetic acid and appropriate deprotection conditions.
1H NMR (d 4 MeOH) :8.37 (1 H, s, Ar) 3.13 (1 H, d, J 8 Hz, Ar); 8.02 j1 H, d, J 8 Hz, Ar); 7.60 (1 H, m, Ar); 7.38 (2 H, s, Ar); 7.18 (1 H, di, L= 8 Hz, Ar); 7.07 (1 H, m, Ar); 5.85 (1 H, s, CH-thiazole); 4.15 (2 H, s, CH 2
NH
2 2.78 (4 H, m, CH 2
CH
2
CH
2 1.-95 (2 H, pentet, J 7 Hz, CH 2
CH
2
CH
2 Hplc (Luna 2, Gradient rt =4.55 minutes.
LC/MS (Luna 2, Gradient rt =3.04 minutes, 479 (M4).
Example 32 3- (Aiinomethyl) benzoyl-D/L-2- (methanesulfonylamino) thiazol-4ylglycine Prepared using methanesulphoriyl chloride 1 H NMR (d 4 MeCOH) 7. 77 (2 H, m. Ar); 7. 48 7. 32 (2 H, m, Ar); 7.26 (1 H, s, Ar); 7.08 (2 H, d, J= 8 Hz, Ar); 6.95 (1 H, d, J 8 Hz, Ar); 6.58 (1 H, s, Ar); 5.61 (1 H, s, CH-thiazole); 3.98B (2 H, s, CH 2
NH
2 2. 78 (3 H, s, SO 2 Me) 2. 65 (4 H, m, 3 0 CH 2
CH
2
CH
2 1. 85 (2 H, pentet, J 5 Hz, CH 2
CH
2
CH
2 Hplc (Luna 2, Gradient rt =3.76 minutes.
LC/MS (Luna 2, Gradient rt =1.89 minutes, 500 Example 33 WO 01/96305 PCT/GB01/02566 -89- 3-(Aminomethyl)benzoyl-D/L-2-ethylthiazol-4-ylglycine 3ethoxycarbonyl-4,5,6,7-tetrahydrobenzo[b]thiophene-2-amide trifluoroacetate salt Synthesised as described for example 12 using N-BOC-D/L-2ethylthiazol-4-ylglycine (which was prepared as described below) and 2-amino-3-ethoxycarbonyl-4,5,6,7tetrahydro[b]thiophene.
N-t-butyloxycarbonyl-D/L-2-ethylthiazol-4-ylglycine A solution of ethyl y-chloro-a-oximinoacetoacetate (2.00 g, 10.3 mmol) and thiopropionamide (0.92 g, 10.3 mmol) in dry benzene (15 mL) was heated at reflux. After 4 hours the reaction mixture was poured onto NaHCO 3 (sat. aq., 50 mL), The resulting mixture was extracted with ethyl acetate (2 x mL), and the combined extracts dried over MgSO 4 and evaporated under reduced pressure. Flash chromatography (ethyl acetate:hexane 1:4) then afforded impure ethyl a-oximino-2ethylthiazole-4-acetate (0.83 The crude oxime was dissolved in methanol (25 mL) and formic acid (50% aq., 10 mL) was added. The mixture was cooled to 0 C and zinc dust (1.00 g, 15.3 mmol) was added in portions over 30 mins. The reaction mixture was allowed to warm to room temperature and stirred for 6 hours. The solution was then filtered, basified to pH 9 with solid NaHCO 3 and extracted with ethyl acetate (3 x mL). The combined extracts were dried (MgSO 4 and evaporated to afford D/L-2-ethylthiazol-4-ylglycine ethyl ester (0.56 g, 2.6 mmol).
The ester (560 mg, 2.6 mmol) was dissolved in tetrahydrofuran mL). Triethylamine (0.4 mL, 3.9 mmol) was added, followed by di-t-butyl dicarbonate (0.57 g, 2.6 mmol). After stirring at room temperature overnight the mixture was concentrated, water (20 mL) was added and the solution extracted with ethyl acetate (2 x 20 mL). The combined extracts were evaporated to WO 01/96305 WO 0196305PCT/GB01/02566 afford N-t-butyloxycarbonyl-D/L-2--ethylthiazol-4-ylglycine ethyl ester (824 mg,) as a golden oil. The oil was dissolved in methanol (25 raL) and sodium hydroxide (2 M ag., 5 mL) was added. After stirring at room temperature for 2 hours, the solution was concentrated, water (30 mL) was added, and the solution extracted with ethyl acetate (30 mL). The aqueous layer was then acidified to pH 4 with 2 N HCl, and extracted with ethyl acetate (2 x 20 mL), The latter extracts were combined and evaporated to afford N-t-butyloxycarbonyl-D/L-2ethylthiazol-4--ylglycine (450 mg) as a white solid.
1 H NIMR (CDCl 3 10.1 (1 H, br s, CO 2 H) 7. 20 (1 H, s, thia zole CR), 5.85 (1 H, bor d, J 6 Hz, NH~oc), 5.52 (1 H, br d, J 6 Hz, ca-CH) 3. 05 (2 H, q, J 5 Hz, CH 2
CH
3 1. 49 (9 H, s, C (CH 3 3 1 42 (3 H, t, J 5 Hz CH 2
CH
3 3- (Aiinomethyl) benzoyl-D/L-2-ethylthiLazol-4-ylglycine 3ethoxycarbonyl-4 7-tetrahydrobenzo thiophene-2-amide trifluoroacetate salt 'H NMP. (d 3 acetonitrile) 8. 05 (1 H, s, Ar) 7. 90 (1 H, d, JT Hz, Ar), 7.60 (1 H, J 15 Hz, Ar), 7.45 (1 H, m, Ar), 7.35 (1 H, s, Ar), 6.00 (1 H, m, CHNH), 4.20 (2 H, q, J 8 Hz, CH 2
CH
3 4. 10 (2 H, S, CH 2
NH
2 2. 95 (2 H, q, J 8 Hz,
CH
2
CH
3 2.70 (2 H, s, benzo[b]thiophenyl CR 2 2.50 (2 H, s, benzolblthioph-enyl CH 2 1.80 (4 H, s, benzo[b]thiophenyl, 2 x
CR
2 1. 30 (3 H, t, J 8 Hz, CR 3 1. 15 (3 H, t, J 8 Hz,
CH
3 Hplc (LUNA 2, Gradient rt 5.17 minutes LC/MS (LUNA 2 Gradient rt 2.69 minutes, 527 (MH) Example 34 3- (.minomethyl)benzoyl-D/L-2-ethylthiazol-4--ylglycine 3-cyano- 4,5,6, 7-tetrahydrobenzo Eb] thiopherie-2-amide trifluoroacetate WO 01/96305 PCT/GB01/02566 -91salt Synthesised as described for example 12 using N-BOC-D/L-2ethylthiazol-4-ylglycine (which was prepared as described in example 33) and 2-amino-3-cyano-4,5,6,7-tetrahydro[b]thiophene (which was prepared using the general procedure below).
Cyclohexanone (10 mmol), malononitrile (10 mmol), acetic acid (8 mmol) and ammonium acetate (2 mmol) were dissolved in benzene (25 mL). The reaction vessel was equipped with a Dean- Stark collector and heated to reflux until water evolution ceased (approx. 6 hours). The mixture was cooled to room temperature, diluted to 100 mL with ethyl acetate, and washed twice with sodium bicarbonate solution (sat. aq., 50 mL) and dried over MgSO 4 Volatile components of the reaction mixture were removed under reduced pressure and the crude product was dissolved in ethanol (20 mL). Sulfur (10 mmol) and morpholine mmol) were added and the mixture was heated at reflux for one hour, when TLC indicated complete consumption of starting material. After cooling, the reaction mixture was diluted to 100 mL with ethyl acetate and extracted with hydrochloric acid (1 N, 2 x 30 mL). The organic portion was then concentrated under reduced pressure to afford crude product which was sufficiently pure to be used without further purification.
3-(Aminomethyl)benzoyl-D/L-2-ethylthiazol-4-ylglycine 3-cyano- 4,5,6,7-tetrahydrobenzo[b]thiophene-2-amide trifluoroacetate salt 1 H NMR (CDCI 3 8.30 (3 H, m, Ar), 7.85 (1 H, s, Ar) 7.65 (1 H, d, J 7 Hz, Ar), 6.15 (1 H, d, J 8 Hz, NHCH), 3.90 (2 H, s,
NH
2
CH
2 2.95 (2 H, q, J= 7 Hz, CH 2
CH
3 2.35 (4 H, br s, benzo[b]thiophenyl, 2 x CH 2 1.65 (4 H, br s, benzo[b]thiophenyl, 2 x CH 2 1.25 (3 H, t, J 7 Hz, CH 3
CH
2 WO 01/96305 PCT/GB01/02566 -92- Hplc (LUNA 2, Gradient rt 4.46 minutes LC/MS (LUNA 2, Gradient rt 2.28 minutes, 480 (MH+) Example 3-(Aminomethyl)benzoyl-D/L-2-methylthiazol-4-ylglycine benzothiazol-2-amide Prepared as described for example 16 but using the protected amino acid N-tbutyloxycarbonyl-D/L-2-methythiazol--ylglycine (which was prepared in the same way as that described for Ntbutyloxycarbonyl-D/L-2-ethylthiazol-4-ylglycine in example 27 but using thioacetamide instead of thiopropionamide) instead of the protected phenylglycine.
IH NMR (d 4 MeOH): 7.84 (2 H, m, Ar); 7.7 (1 H, d, J= 9 Hz, Ar); 7.58 (1 H, d, J 9 Hz, Ar); 7.52 7.38 (2 H, m, Ar); 7.35 (1 H, s, Ar); 7.26 (1 H, t, J 6 Hz, Ar); 7.14 (1 H, t, J 6 Hz, Ar); 5.95 (1 H, s, CH-thiazole); 4.03 (2 H, s, CH- 2
NH
2 2.57 (3 H, s, CH 3 Hplc (Luna 2, Gradient rt 3.56 minutes.
LC/MS (Luna 2, Gradient rt 1.68 minutes, 438 (MH) The compounds exemplified hereinabove have been found to be inhibitors of tryptase by the method of Tapparelli et al., (1993) J. Biol. Chem., 268, 4734 to 4741.

Claims (33)

1. A tryptase inhibitor compound of formula (I) R Cy x *L Lp H 2 N R 6 a (1) where: R, represents amino, hydroxy, aminomethyl, hydroxymethyl or hydrogen; represents hydrogen or methyl; X-X is selected from -CH=CH-, -CONRia,-i -NH-CO-, -NRa-CH 2 -CH 2 -NRia-i -CH 2 -OCH 2 -COO-, and -CH 2 CH 2 represents hydrogen, (l-6C)alkyl or phenyl(l-6C)alkyl; L is CO or CONRld(CH 2 )m in which m is 0 or 1 and Rid is hydrogen, (1-6C)alkyl or phenyl (l-6C)alkyl; Cy is cycloalkyl, piperidinyl, 3,4-methylenedioxyphenyl, furyl, thienyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl, pyrazinyl, naphthyl, benzofuryl or benzo[blthienyl group, optionally substituted by or R 31 Xj in which Xi is a bond, 0, NH, CO, CONH, NHCO, SO,, NHISO, or SONH, CI- 2 and R 3 i is phenyl or pyridyl optionally substituted by R 3 ,ai each R~a independently is hydrogen, hydroxyl, (1-6C) alkoxy, (1-6C) alkyl, (2-CC)alkenyl, (2-6C)alkynyl, (1- 6C) alkanoyl, (1-6C) alkylaminoalkyl, hydroxy(l-6C) alkyl, carboxy, (1-6C) alkoxyalkyl, (1-6C) alkoxycarbonyl, (1-6C) alkylaminocarbonyl, amino (l-6C)alkyl CONH 2 CH 2 CONH 2 aminoacetyl, (1-Ge) alkanoylamino, hydroxy(l-6C) alkanoylamino, amino (l-6C) alkanoylamino, (l-6C) alkylamino (1-Ge) akanoylanino, di(1-6C)alkylaraino(1-6C)alkanoylamino, (1-6C) alkoxycarbonylamino, amino, halo, cyano, nitro, thiol, 1-6C) alkylthio, (1-6C) alkylsuiphonyl, (1-6C) alkylsuiphenyl, WO 01/96305 WO 0196305PCT/GB01/02566 -94- imidazolyl, hydrazido, (l-6C)alkylimidazolyl, (1-6C) alkylsuiphonamido, 6C) alkylaminosulphonyl, aminosuiphonyl, (1-6C) haloalkoxy, or haloalkyl; and Lp is a lipophilic group; or a physiologically tolerable salt thereof.
2. A compound as claimed in Claim 1, in which R 5 is amino or hydrogen.
3. A compound as claimed in Claim 2, in which P. is hydrogen.
4. A compound as claimed in any one of Claims I to 3, in which R~a is hydrogen. A compound as claimed in any one of Claims 1 to 4, in which X-X is CONH.
6. A compound as claimed in any one of Claims 1 to 5, in which the alpha carbon atom has the conformation that would result from construction from a D-oc-aminoacid NH 2 -CH (Cy) COOH where the NH 2 represents part of X-X.
7. A compound as claimed in any one of Claims 1 to 6, in which Cy is cyclohexyl, piperidin-4-yl, 3,4-methylenedioxy- phenyl, fur-2-yl, thien-2-yl, thien-3-yl, imidazol-4-yl, oxazol-4-yl, oxazol-5-yl, thiazol-4-yl, thiazol-5-yl, pyrid-2- yl, pyrid-3-yl, pyrid-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrazin-2-yl, pyrazin-3-yl, naphth-l-yl, naphth-2-yl, indol-5-yl, indan-5-yl, 3,4-dihydrobenzofur-5-yl, benzofur-2-yl or benzo[b]thien-2-yl group, optionally substituted by or R 3 jXj in which Xi is a bond, 0, NH or CH 2 and R 3 1 is phenyl optionally substituted by R 3 a*'
8. A compound as claimed in any one of Claims 1 to 7, in which R 3 a is hydrogen; hydroxyl; methoxy; ethoxy; isopropoxy; methyl; ethyl; isopropyl; acetyl; propanoyl; isopropanoyl; WO 01/96305 WO 0196305PCT/GB01/02566 methylaminomethyl; dimethylaminomethyl; hydroxymethyl; carboxy; inethoxymethyl; methoxycarbonyl; ethoxycarbonyl; inethylaminocarboiyl; dimethylaminocarbonyl; aminomethyl; CONH 2 CH 2 CONH 2 aminoacetyl; formylamino; acetylamino; hydroxyacetylamino, amiricacetylamino, methylaminoacetylamino, dimethylaininoacetylamino r methoxycarbonylamiic; ethoxycarbonylamino; t-butoxycarbonylamino; amino; fluoro; chioro; cyano; nitro; thiol; methylthio; methylsuiphonyl; ethylsuiphonyl; methylsuiphenyl; imidazol-4-yl; hydrazido; 2-methylinidazol-4- yl; methylsulphoriylamido; ethylsuiphonylamido; methylaminosulphonyl; ethylaminosulphonyl; aminosuiphonyl; trifluoromethoxy or trifluoromethyl; and R 3 iXi is phenyl, phenoxy, phenylamino or benzyl.
9. A compound as claimed in Claim 8, in which Cy is selected from cyclohexyl, piperidin-4-yl, l-acetylpiperidin-4-yl, 1- prcpanoylpiperidin-4-yl, l-isobutyrylpiperidin-4-yl, 1- aminoacetylpiperidin-4-yl, 5-methylfur-2-yl, imidazol-4 -yl, 2- methylthiazol-4-yl, 2-aminothiazol-4-yl, 2-formylaminothiazol- 4-yl, 2-aminothiazol-5-yl, 2-formylaminothiazol-5-yl, 2- phenylthiazol-4-yl, 4-aminopyrid-3-yl, 6-methylpyrid-2-yl, 3- aminopyrid-4-yl, naphth-1-yl, naphth-2-yl, benzofur-2-yl, 3- methylbenzothien-2-yl, 6-aminopyrid-3-yl, 2-ethylthiazol-4-yl, 2-benzylthiazol-4-yl, 2-methylsulfonamidothiazol-4-yl, 2- chloropyrid-3-yl, 2-hydroxyacetylaminothiazol-4-yl, 2-N,N- dimethylaminoacetylaminothiazol-4-yl, indol-5-yl, and 3, 4-dihydrobenzofur-2-yl.
10. A compound as claimed in any one of Claims 1 to 10, in which Cy is a group of formula WO 01/96305 WO 0196305PCT/GB01/02566 -96- R 3 r xa in which one of Xa and Xb is N and the other is NH or S, and each of R~r and PR,, is as defined for R,,a.
11. A compound as claimed in Claim 10, in which Xa is S and X' is N.
12. A compound as claimed in Claim 10 or Claim 11, in which R 3 is hydrogen and R 3 is hydrogen, (l-6C)alkyl, amino, (1- 6C) alkanoylamino, hydroxy(I-6C) alkanoylamino, N,N-di (1- 6C) alkylaminoalkanoylamino, (l-6C) alkylsulfonylamino, phenyl or benzyl.
13. A compound as claimed in any one of Claims 1 to 10 in which Cy is pyrid-2-yl, pyrimid-2-yl, pyrimid-4-yl, pyrazin-2- yl, pyrazin-3-yl or oxazol-4-yl, optionally substituted by R,, or
14. A compound as claimed in any one of Claims 1 to 13, in which Cy is cycloalkyl, piperidinyl, 3,4-methylenedioxyphenyl, furyl, thienyl, imidazolyl, thiazolyl, pyridyl, naphthyl or benzofuryl group, optionally substituted by or R 3 iXi in which Xi is a bond, 0, NH or CH, and R 3 j is phenyl optionally substituted by Ra or R 3 jXj in which Xi is a bond, 0, NH or CH, and R 3 i is phenyl optionally substituted by R 3 and each R 3 independently is hydrogen, hydroxyl, (1-6C) alkoxy, (1-6C) alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (l-6C)alkanoyl, (1-6C) alkylaminoalkyl, hydroxy (l-6C) alkyl, carboxy, (1-6C) alkoxyalkyl, (l-6C) alkoxycarbonyl, (1-6C) alkylaminocarbonyl, amino (l-6C)alkyl CONH 2 CH 2 CONH 2 aminoacetyl, (1- 6C) alkanoylaraino., (1-6C) alkoxycarbonylanino, amino, halo, cyano, nitro, thiol, 1-6C) alkylthio, (1-6C) alkylsuiphonyl, WO 01/96305 WO 0196305PCT/GB01/02566 -97- (1-6C) alkv~lsulphenyl, imidazolyl, hydrazido, (1-GC) alkylimidazolyl, (1-GC) alkylsuiphonamido, (1-6e) alkylaminosuiphonyl, aminosuiphonyl, (1-6C) haloalkoxy, or (1- 6e) haloalkyl. A compound as claimed in any one of Claims 1 to 14, in which Cy is an optionally substituted cycloalkyl, piperidinyl, thienyl, thiazolyl, pyridyl or naphthyl group and each independently is hydrogen, hydroxyl, (1-6e) alkoxy, (1-6C) alkyl, (1-Ge) alkylaminoalkyl, hydroxy(l-GC)alkyl, (1- Ge) alkoxyalkyl, (1-6C) alkoxycarbonyl, (1-6C) alkylaminocarbonyl, amino (1-Ge) alkyl CONH,, CHCONH 2 aminoacetyl, (1-Ge) alkanoylamino, (1-GC) alkoxycarbonylamino, amino, halo, cyano, nitro, thiol, (1-GC) alkylthio, (1-6C) alkylsulphonyl, (1-6C) alkylsulphenyl, imiclazolyl, hydrazido, (l-GC)alkyilimidazolyl, (1-Ge) alkylsulphonamido, (1-Ge) alkylaminosulphonyl, aminosuiphonyl, (1-GC) haloalkoxy, or (1- 6C) haloalkyl.
16. A compound as claimed in any one of Claims I to 15, in which L represents CO, CONH, CONCH, or CONHCH 2
17. A compound as claimed in Claim 16, in which L is CO, CONH or CONCH 3
18. A compound as claimed in any one of Claims 1 to 17, in which Lp is an alkyl, alkenyl, carbocyclic or heterocyclic group, or a combination of two or more such groups linked by a spiro linkage or a single or double bond or by C=O, 0, OCO, coo, S, so, SO,, CONRe, NRie-CO- or NR,, linkage (where R,,e is as defined for Ria,), optionally substituted by one or more oxo or R, groups in which R, is an amino acid residue, N-Cl1- Ge) alkylaminocarbonyl, N,N-di (1-6C) alkylaminocarbonyl, N- (1- Ge) alkylamino (l-GC) alkanoyl, N- (1-Ge) alkanoylamino (1- SC) alkanonyl, C-hydroxyamino (1-Ge) alkanoyl, hydroxy(2- Ge) alkanoylamino (1-GC)alkanoyl, di (1-Ge)alkylaminosulfonyl, hydrogen, hydroxyl, (1-6C)alkoxy, (1-6C)alkanoyloxy, (1-Ge) alkyl, (2-GC)alkenyl WO 01/96305 WO 0196305PCT/GB01/02566 -98- (2-6C)alkynyi, (3-6C)alkenyloxycarbonyl, (l-6C)alLkanoyl, amino (1-6C) alkyl, amido (CONH,), amino (1-6C) alkanoyl, aminocarbonyl (1-50)alkarioyl, hydroxy (1-60) alkyl, carboxy, hydroxy(1-6C)alkanoyl, (1-6C)alkoxy(1-6C)alkyl, (1- GC)alkoxycarbonyl (1-5C)alkyl, (l-6C)alkoxycarbonyl, (I- 6C)alkanoylamino, amino, halo, cyano, nitro, thiol, (1-6C) alkyithia, (l-6C)alkylsulfonyl, (1- 6C)alkylsulphenyl and hydrazido.
19. A compound as claimed in Claim 18, in which R, is selected f rom N-acetylalaninoyl; serinoyl; threoninoyl; aspartoyl; glutamoyl; N- 3-dimethyl) butylamino-carbonyl; N-methyl -N-ethylaminocarbonyl; N-methylacetyl; 2-N- acetylaminoacetyl; 2-N-acetylaminopropanoyl; 2-N- (2- methyipropanoyl) aminoacetyl; 2 -amino-3 -hydroxypropanoyl; 2- amino-3 -hydroxybutanoyl; 2 -hydroxyacetylaminoacetyl; dimethylaminosulfonyl; hydrogen; hydroxyl; methoxy; acetoxy; methyl; ethyl; propyl; 2-propyl; 2,2-dimethylethyl; allyl; propynyl; allyloxycarbonyl; acetyl; propionyl; isobutyryl; aminomethyl; CONH 2 aminoacetyl; aminopropionyl; 2- aminopropionyli aminocarbonylacetyl; hydroxymethyl; 1- hydroxyethyl; carboxy; 2 -hydroxyacetyl; 2-hydroxypropanoyl; methoxyniethyl; methoxycarboriylmethyl; methoxycarbonyl; ethoxycarbonyl; formylamino; acetylamino; amino; chloro; cyano; nitro; thiol; methylthio; methylsuiphonyl; ethyl sulfonyl; methylsulphenyl; and hydrazido. A compound as claimed in Claim 18 or Claim 19, in which in which L represents CO and Lp represents N WO 01/96305 WO 0196305PCT/GB01/02566 -99- -N R 3 N
21. A compound as claimed in Claim 20, in which R, represents hydrogen, hydroxyl or (1-6C) alkylaminocarbonyl.
22. A compound as claimed in Claim 18 or Claim 19, in which L represents CONH and Lp represents R R 3 N X N N 0 WO 01/96305 WO 0196305PCT/GB01/02566 -100- S\ R R3SR 3 SS R 3 S P RR 3 in which X is CH or N.
23. A compound as claimed in Claim 22, in which each R, is selected independently from hydrogen, amino, hydroxy, (1- 6C)alkyl, (l-6C)alkanoyl, (1-6C)alkanoyloxy, (1- alkoxycarbonyl (:l-C)alkyl, arnino(1-6C) alkyl and cyano.
24. A compound as claimed in Claim 18 or Claim 19, in which L represents CONRid and Lp represents '-OR3 in which R, is (1-6C) alkylaminocarbonyl, N- (1-6C) alkylamino (1- 1S 6C)alkanoyl, N- (i-EC)alkanoylamino(l-6C)alkanonyl, C- hydroxyamino (1-6C) alkanoyl, hydrogen, (l-6C) alkoxy, (1- 6C) alkyl, amino(1-GC) alkyl, aminocarbonyl, hydroxy(l-6C) alkyl, (l-6C)alkoxy(1-6C)alkyl, (l-6C)alkoxycarbonyl, (1- 6C) acyloxymethoxycarbonyl, (l-6C)alkylamino, amino, halo, cyano, nitro, thiol, (1-6C) alkylthio, (l-6C) alkylsuiphonyl, (1-6C) alkylsuiphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, (l-6C) alkylimidazolyl, thiazolyl, (1- GC) alkyithiazolyl, (l-6C) alkyloxazolyl, oxazolyl, (1- 6C) alkylsuiphonamido, (1-6C) alkyjlaminosulphonyl, aminosuiphonyl, (l-6C)haloalkoxy or (1-6C)haloalkyl. A compound as claimed in Claim 24, in which Ep is phenyl, 3 -cyano-4-methyiphenyl, 3 -arinocarbonyiphenyl, 4- WO 01/96305 PCT/GB01/02566 -101- aminocarbonyl-phenyl, 4-chloro-3-aminocarbonyl-phenyl, 4- chlorophenyl, 3,5-dichlorophenyl, 3-aminomethylphenyl, 4- methyl-3-acetylaminophenyl, 4-(l-hydroxethyl)phenyl and 4- isopropylphenyl.
26. A compound as claimed in Claim 18 or Claim 19, in L represents CONR and Lp represents in which R3x represents R 3 or a group of formula -Rj in which p is 0 or 1; XY, represents CO, COO, CONH or SO,; GI represents (l-3C)alkanediyl, CH 2 OCH, or, when p is 1, a bond; and Rj represents a carbocyclic or heterocyclic group, optionally substituted by R 3
27. A compound as claimed in Claim 26, in which L represents CONH and R3x represents R 3 or a group of formula -(CO)p-(Gi)-Rj in which p is 0 or 1; G 1 represents (l-3C)alkanediyl or, when p is 1, a bond; and Rj represents a carbocyclic or heterocyclic group, optionally substituted by R 3
28. A compound as claimed in Claim 26, in which Lp is selected from WO 01/96305 WO 0196305PCT/GB01/02566 -102- N N rR 3 0 N N R 0 WO 01/96305 WO 0196305PCT/GB01/02566 -103- N NSol R 3 so 2 -R 3 so 3 R NN N in which when R. is a substituent on the 1-position of a 2,3-dihaydroindolyl group, it represents an amino acid residue; (1-6C) alkylaminocarbonyl; N (l-GC) alkylamino(1-GC) alkanoyl; N- alkanoylaminoalkanonyl; C-hydroxyamino 6C) alkaricyl; hydroxy(1-6C) alkancylamino (1-6C)ailkanoyl; di (1- GC) alkylaminosulfonyl; hydrogen; (1-6C) alkyl; (1-6C) alkanoyl; (1-6C) alkoxycarbonyl; (l-6C) acyloxymethoxycarbonyl; amino (1- 6C) alkyl; amido (CQNR 2 amino (1-6C) alkanoyl; aminocarbonyli(1- 6C)alkanoyl; hydroxy(l-6C)alkyl; hydroxy(I-6C)alkanoyl; (1- GC)alkoxy(1-6C)alkyl; (1-6C)alkoxycarbonyl (1-6C)alkyl; (1- 6C) alkoxycarbonyl; (1-6C) alkanoylamino; or (1- 6C)alkylsulfonyl; and (ii) when R, is a substituent on a cyclohexyl, phenyl, naphthyl, thiazolyl, imidazolyl, pyridyl or quinolinyl group, it is hydrogen, hydroxy, amino, alkanoylamino, alkyl, aminoalkyl or alkanoylaminoalkyl.
29. A compound as claimed in Claim 18 or Claim 19, in which L represents CONR 1 d and Lp represents R 3 y R 3 RR 3yI, IR WO 01/96305 PCT/GB01/02566 -104- in which R3y represents R 3 or a group of formula Rk-G 2 in which G 2 represents a bond or (1-3C)alkanediyl, Xa represents a bond, CO, OCO, COO or NHCO, and Rk represents a carbocyclic or heterocyclic group, optionally substituted by R 3 A compound as claimed in Claim 29, in which Lp is selected from RX-co R O-CO 0 N-CO 1 s3 N H -105- \O in which when R 3 is present as a substituent at the 3- position of a 4,5,6,7-tetrahydrobenzothiophene group, it represents a carboxy group; a (l-6C)alkoxycarbonyl group; or a (1-6C)alkylaminocarbonyl group; and (ii) when R 3 is present as a substituent on a phenyl or pyridyl group, it is a hydrogen atom.
31. A compound as claimed in Claim 18 or Claim 19, in which L represents CONRd and Lp represents R3 R3 N N N 3 I-C A) I S or S or
32. A compound as claimed in Claim 31, in which the heterocyclic group is substituted by one or two R 3 groups.
33. A compound as claimed in Claim 32, in which each R 3 group is selected from hydrogen, halogen, (1-6C)alkyl and (1- 6C)alkoxy.
34. A compound as claimed in Claim 18 or Claim 19, in which L represents CONRI, and Lp represents I I I S S R 3 y S 0 S in which R 3y is as defined in claim 28, X, is O, S or NR, in which R Z is independently selected from one of the values for R 3 y, and Xza is CH 2 or is as defined for X,. A compound of formula I as claimed in Claim 1, r or a physiologically tolerable salt thereof, substantially as hereinbefore described with reference to any one of Examples 1 to 32.
36. A pharmaceutical composition which comprises a compound as claimed in any one of claims 1 to 35 together with at least one pharmaceutically acceptable carrier or excipient.
37. A compound as claimed in any one of claims 1 to 35 for use in therapy.
38. Use of a compound as claimed in any one of claims 1 to 35 for the manufacture of a medicament for treating a condition responsive to a tryptase inhibitor in a human or non-human animal. to 39. The use of claim 38 wherein the condition is selected from the group consisting of asthma, allergic rhinitis, eczema, psoriasis, atopic dermatitis, uriticaria, rheumatoid arthritis, conjunctivitis, inflammatory bowel disease, neurogenic inflammation, atherosclerosis and cancer. The use of claim 39, wherein the condition is asthma. 1s 41. A method for treatment of a condition responsive to a tryptase inhibitor, said method comprising administration to a human or a non-human animal of a therapeutically effective amount of a compound of any one of claims 1-35, or a pharmaceutical composition of claim 36.
42. A compound according to any one of claims 1-35 or a pharmaceutical composition according to claim 36, when used for treating a condition responsive to a tryptase inhibitor. Dated 15 May, 2006 Tularik Limited Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON IR:\LIB 115 796.doc: LAM
AU2001264077A 2000-06-13 2001-06-12 Serine protease inhibitors Ceased AU2001264077B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/GB2000/002291 WO2000077027A2 (en) 1999-06-14 2000-06-13 Serine protease inhibitors
AU55460/00 2000-06-13
PCT/GB2000/004764 WO2001044226A1 (en) 1999-12-14 2000-12-13 Serine protease inhibitors
AU18713/01 2000-12-13
PCT/GB2001/002566 WO2001096305A1 (en) 2000-06-13 2001-06-12 Serine protease inhibitors

Publications (3)

Publication Number Publication Date
AU2001264077C1 true AU2001264077C1 (en) 2001-12-24
AU2001264077A1 AU2001264077A1 (en) 2002-03-14
AU2001264077B2 AU2001264077B2 (en) 2006-08-10

Family

ID=26243532

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001264077A Ceased AU2001264077B2 (en) 2000-06-13 2001-06-12 Serine protease inhibitors
AU6407701A Pending AU6407701A (en) 2000-06-13 2001-06-12 Serine protease inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU6407701A Pending AU6407701A (en) 2000-06-13 2001-06-12 Serine protease inhibitors

Country Status (4)

Country Link
JP (1) JP2004503538A (en)
AU (2) AU2001264077B2 (en)
DE (1) DE60124397T2 (en)
WO (1) WO2001096305A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0114185D0 (en) 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
CN108141296B (en) * 2015-11-05 2020-12-18 苹果公司 Synchronization signal used to authorize secondary access
EP3665820B1 (en) * 2017-08-10 2025-10-01 Panasonic Intellectual Property Corporation of America User equipment, base station and wireless communication method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000005312A (en) * 1996-04-10 2000-01-25 오노 야꾸힝 고교 가부시키가이샤 Tryptase inhibitor and novel guanidino derivatives
WO1999011658A1 (en) * 1997-08-29 1999-03-11 Proteus Molecular Design Ltd. Meta-benzamidine derivatives as serin protease inhibitors
WO1999026925A1 (en) * 1997-11-26 1999-06-03 Yoshitomi Pharmaceutical Industries, Ltd. Tryptase inhibitors comprising heterocyclic amide compounds
EP1073624A1 (en) * 1998-04-24 2001-02-07 Proteus Molecular Design Limited Aminomethyl-benzoic ester derivatives as tryptase inhibitors
GB9929552D0 (en) * 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
AU5546000A (en) * 1999-06-14 2001-01-02 Protherics Molecular Design Limited Compounds
EP1192132B1 (en) * 1999-06-14 2005-09-07 Eli Lilly And Company Serine protease inhibitors
GB0030303D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030304D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds

Also Published As

Publication number Publication date
DE60124397D1 (en) 2006-12-21
DE60124397T2 (en) 2007-10-11
AU6407701A (en) 2001-12-24
JP2004503538A (en) 2004-02-05
AU2001264077B2 (en) 2006-08-10
WO2001096305A1 (en) 2001-12-20

Similar Documents

Publication Publication Date Title
US7067516B2 (en) Serine protease inhibitors
US7157585B2 (en) Serine protease inhibitors
AU2002222207A1 (en) Serine protease inhibitors
US6855715B1 (en) Serine protease inhibitors
WO2000077027A2 (en) Serine protease inhibitors
ES2291464T3 (en) DERIVATIVES OF N- (ARILSULFONIL) BETA-AMINO ACIDS THAT INCLUDE A REPLACED AMINO ATILE GROUP, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
JP2002518985A (en) Protein isoprenyltransferase inhibitors
US7381734B2 (en) Serine protease inhibitors
AU2001264077C1 (en) Serine protease inhibitors
AU2001264077A1 (en) Serine protease inhibitors
CA2413061C (en) Serine protease inhibitors
ZA200304384B (en) Serine protease inhibitors.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 JAN 2007.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 JAN 2007

MK14 Patent ceased section 143(a) (annual fees not paid) or expired